Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31838561,Objective response rates,Objective response rates were 50.0% (95% CI 37.4-62.6%) for Oral-VRL and 53.7% (95% CI 41.1-66.0%) for IV-VRL.,"Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31838561/),%,50.0,59,DB00445,Epirubicin
,31838561,Objective response rates,Objective response rates were 50.0% (95% CI 37.4-62.6%) for Oral-VRL and 53.7% (95% CI 41.1-66.0%) for IV-VRL.,"Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31838561/),%,53.7,60,DB00445,Epirubicin
,8324872,plasma clearance,"In a model-independent framework, mean EPI plasma clearance was identical at the two dose levels of 60 and 120 mg/m2 (65.4 +/- 8.0 vs 65.3 +/- 13.4 l/h, P = 0.92).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [h],65.4,3958,DB00445,Epirubicin
,8324872,plasma clearance,"In a model-independent framework, mean EPI plasma clearance was identical at the two dose levels of 60 and 120 mg/m2 (65.4 +/- 8.0 vs 65.3 +/- 13.4 l/h, P = 0.92).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [h],65.3,3959,DB00445,Epirubicin
,8324872,MRT,"Both the mean residence time (MRT) and the volume of distribution at steady-state (VSS) were similar as well (MRT: 22.6 +/- 2.9 vs 24.2 +/- 3.7 h; P = 0.46; VSS: 21.3 +/- 1.5 vs 22.6 +/- 6.5 l/kg, P = 0.46).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),h,22.6,3960,DB00445,Epirubicin
,8324872,MRT,"Both the mean residence time (MRT) and the volume of distribution at steady-state (VSS) were similar as well (MRT: 22.6 +/- 2.9 vs 24.2 +/- 3.7 h; P = 0.46; VSS: 21.3 +/- 1.5 vs 22.6 +/- 6.5 l/kg, P = 0.46).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),h,24.2,3961,DB00445,Epirubicin
,8324872,VSS,"Both the mean residence time (MRT) and the volume of distribution at steady-state (VSS) were similar as well (MRT: 22.6 +/- 2.9 vs 24.2 +/- 3.7 h; P = 0.46; VSS: 21.3 +/- 1.5 vs 22.6 +/- 6.5 l/kg, P = 0.46).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [kg],21.3,3962,DB00445,Epirubicin
,8324872,VSS,"Both the mean residence time (MRT) and the volume of distribution at steady-state (VSS) were similar as well (MRT: 22.6 +/- 2.9 vs 24.2 +/- 3.7 h; P = 0.46; VSS: 21.3 +/- 1.5 vs 22.6 +/- 6.5 l/kg, P = 0.46).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [kg],22.6,3963,DB00445,Epirubicin
,8324872,"plasma clearance, PlCl","No statistically significant difference could be found in mean statistical-moment-theory parameters determined after 75- and 150-mg/m2 EPI doses (plasma clearance, PlCl: 83.4 +/- 13.5 vs 68.5 +/- 12.8 l/h, P = 0.12; MRT: 22.6 +/- 4.8 vs 21.9 +/- 3.9 h, P = 0.60; VSS: 26.7 +/- 10.5 vs 21.2 +/- 7.0 l/kg, P = 0.17).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [h],83.4,3964,DB00445,Epirubicin
,8324872,"plasma clearance, PlCl","No statistically significant difference could be found in mean statistical-moment-theory parameters determined after 75- and 150-mg/m2 EPI doses (plasma clearance, PlCl: 83.4 +/- 13.5 vs 68.5 +/- 12.8 l/h, P = 0.12; MRT: 22.6 +/- 4.8 vs 21.9 +/- 3.9 h, P = 0.60; VSS: 26.7 +/- 10.5 vs 21.2 +/- 7.0 l/kg, P = 0.17).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [h],68.5,3965,DB00445,Epirubicin
,8324872,MRT,"No statistically significant difference could be found in mean statistical-moment-theory parameters determined after 75- and 150-mg/m2 EPI doses (plasma clearance, PlCl: 83.4 +/- 13.5 vs 68.5 +/- 12.8 l/h, P = 0.12; MRT: 22.6 +/- 4.8 vs 21.9 +/- 3.9 h, P = 0.60; VSS: 26.7 +/- 10.5 vs 21.2 +/- 7.0 l/kg, P = 0.17).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),h,22.6,3966,DB00445,Epirubicin
,8324872,MRT,"No statistically significant difference could be found in mean statistical-moment-theory parameters determined after 75- and 150-mg/m2 EPI doses (plasma clearance, PlCl: 83.4 +/- 13.5 vs 68.5 +/- 12.8 l/h, P = 0.12; MRT: 22.6 +/- 4.8 vs 21.9 +/- 3.9 h, P = 0.60; VSS: 26.7 +/- 10.5 vs 21.2 +/- 7.0 l/kg, P = 0.17).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),h,21.9,3967,DB00445,Epirubicin
,8324872,VSS,"No statistically significant difference could be found in mean statistical-moment-theory parameters determined after 75- and 150-mg/m2 EPI doses (plasma clearance, PlCl: 83.4 +/- 13.5 vs 68.5 +/- 12.8 l/h, P = 0.12; MRT: 22.6 +/- 4.8 vs 21.9 +/- 3.9 h, P = 0.60; VSS: 26.7 +/- 10.5 vs 21.2 +/- 7.0 l/kg, P = 0.17).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [kg],26.7,3968,DB00445,Epirubicin
,8324872,VSS,"No statistically significant difference could be found in mean statistical-moment-theory parameters determined after 75- and 150-mg/m2 EPI doses (plasma clearance, PlCl: 83.4 +/- 13.5 vs 68.5 +/- 12.8 l/h, P = 0.12; MRT: 22.6 +/- 4.8 vs 21.9 +/- 3.9 h, P = 0.60; VSS: 26.7 +/- 10.5 vs 21.2 +/- 7.0 l/kg, P = 0.17).",Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8324872/),[l] / [kg],21.2,3969,DB00445,Epirubicin
,12621462,MTD,Mucositis was the dose-limiting toxicity and the MTD was 60 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),mg,60,5056,DB00445,Epirubicin
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],7.7,5057,DB00445,Epirubicin
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],26.3,5058,DB00445,Epirubicin
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],14.8,5059,DB00445,Epirubicin
,12621462,C(max),C(max) of Idarubicin and idarubicinol were 7.7+/-2.0 and 26.3+/-9.7 ng/ml at 40 mg/m(2) and increased to 14.8+3.0 and 47.4+12.6 ng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[ng] / [ml],47.4,5060,DB00445,Epirubicin
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],423.2,5061,DB00445,Epirubicin
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],2581,5062,DB00445,Epirubicin
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],732.8,5063,DB00445,Epirubicin
,12621462,AUCt(0-264),AUCt(0-264) of idarubicin and idarubicinol increased from 423.2+/-111.6 and 2581+/-606 hng/ml at 40 mg/m(2) to 732.8+/-140.2 and 4590+/-1258 hng/ml at 70 mg/m(2).,High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),[hng] / [ml],4590,5064,DB00445,Epirubicin
,12621462,Conversion rates,"Conversion rates after HD-Ida and HD-TM were 28.6 and 38.5%, respectively.",High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),%,28.6,5065,DB00445,Epirubicin
,12621462,Conversion rates,"Conversion rates after HD-Ida and HD-TM were 28.6 and 38.5%, respectively.",High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621462/),%,38.5,5066,DB00445,Epirubicin
,6593309,t1/2,4'-epi-DX gave plasma levels constantly lower than those observed after DX; the pharmacokinetic study showed that 4'-epi-DX was eliminated from the body more rapidly (t1/2 30 hours as compared with 43 hours).,Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6593309/),h,30,11038,DB00445,Epirubicin
,6593309,t1/2,4'-epi-DX gave plasma levels constantly lower than those observed after DX; the pharmacokinetic study showed that 4'-epi-DX was eliminated from the body more rapidly (t1/2 30 hours as compared with 43 hours).,Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6593309/),h,43,11039,DB00445,Epirubicin
,7693418,half-lives,"The pharmacokinetic properties of epirubicin are characterised by a triphasic plasma clearance, with half-lives for the initial (alpha), intermediate (beta) and terminal (gamma) elimination phases of approximately 3 minutes, 1 hour and 30 hours, respectively.",Epirubicin. Clinical pharmacology and dose-effect relationship. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693418/),min,3,11261,DB00445,Epirubicin
,7693418,half-lives,"The pharmacokinetic properties of epirubicin are characterised by a triphasic plasma clearance, with half-lives for the initial (alpha), intermediate (beta) and terminal (gamma) elimination phases of approximately 3 minutes, 1 hour and 30 hours, respectively.",Epirubicin. Clinical pharmacology and dose-effect relationship. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693418/),h,1,11262,DB00445,Epirubicin
,7693418,half-lives,"The pharmacokinetic properties of epirubicin are characterised by a triphasic plasma clearance, with half-lives for the initial (alpha), intermediate (beta) and terminal (gamma) elimination phases of approximately 3 minutes, 1 hour and 30 hours, respectively.",Epirubicin. Clinical pharmacology and dose-effect relationship. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693418/),h,30,11263,DB00445,Epirubicin
,7693418,total plasma clearance,"The total plasma clearance of epirubicin is approximately 50 L/h/m2, which is almost 2-fold higher than that of doxorubicin.",Epirubicin. Clinical pharmacology and dose-effect relationship. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7693418/),[l] / [h·m2],50,11264,DB00445,Epirubicin
,10363621,half-life time,The mean phenazone half-life time was significantly shorter in patients with AML (8.79 (3.01) h) than in control group (11.08 (3.61) h) (p < 0.012).,Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),h,8.79,14193,DB00445,Epirubicin
,10363621,half-life time,The mean phenazone half-life time was significantly shorter in patients with AML (8.79 (3.01) h) than in control group (11.08 (3.61) h) (p < 0.012).,Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),h,11.08,14194,DB00445,Epirubicin
,10363621,half-life time,"The mean phenazone half-life time was significantly longer (18.08 (8.80) h) and the mean metabolic clearance rate was significantly smaller (33.92 (15.40) ml/min) after chemotherapy in comparison with the initial value, before treatment (10.22 (2.90) h), (p < 0.01) (50.33 (20.29) ml/min) (p < 0.008).",Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),h,18.08,14195,DB00445,Epirubicin
,10363621,metabolic clearance rate,"The mean phenazone half-life time was significantly longer (18.08 (8.80) h) and the mean metabolic clearance rate was significantly smaller (33.92 (15.40) ml/min) after chemotherapy in comparison with the initial value, before treatment (10.22 (2.90) h), (p < 0.01) (50.33 (20.29) ml/min) (p < 0.008).",Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),[ml] / [min],33.92,14196,DB00445,Epirubicin
,10363621,metabolic clearance rate,"The mean phenazone half-life time was significantly longer (18.08 (8.80) h) and the mean metabolic clearance rate was significantly smaller (33.92 (15.40) ml/min) after chemotherapy in comparison with the initial value, before treatment (10.22 (2.90) h), (p < 0.01) (50.33 (20.29) ml/min) (p < 0.008).",Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),h,10.22,14197,DB00445,Epirubicin
,10363621,metabolic clearance rate,"The mean phenazone half-life time was significantly longer (18.08 (8.80) h) and the mean metabolic clearance rate was significantly smaller (33.92 (15.40) ml/min) after chemotherapy in comparison with the initial value, before treatment (10.22 (2.90) h), (p < 0.01) (50.33 (20.29) ml/min) (p < 0.008).",Phenazone as a marker of liver-metabolic function in patients with acute leukemia. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10363621/),[ml] / [min],50.33,14198,DB00445,Epirubicin
,11038035,time to progression (TTP),"After an overall median follow-up time of 22 months (range 4-39+), the median time to progression (TTP) was 4.5 months and the median duration of response was 8 months (range 3-16).",Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038035/),month,4.5,15145,DB00445,Epirubicin
,11038035,duration of response,"After an overall median follow-up time of 22 months (range 4-39+), the median time to progression (TTP) was 4.5 months and the median duration of response was 8 months (range 3-16).",Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038035/),month,8,15146,DB00445,Epirubicin
,19238629,Objective response rates,"Objective response rates of 65% (95% confidence interval (CI): 43-82), disease stabilisation of 25% (95% CI: 11-47) and a disease control rate (CR + PR + SD) of 90% were achieved overall.","Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238629/),%,65,18433,DB00445,Epirubicin
,19238629,MTD,"The MTD of matuzumab in combination with ECX was 800 mg weekly, and at this DL it was well-tolerated and showed encouraging antitumour activity.","Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19238629/),mg,800,18434,DB00445,Epirubicin
,27789365,zeta potential,"The PSA-BS18 modified liposomal epirubicin (EPI-SL), had a particle size of 133.63±0.92nm, a zeta potential of -26.23±1.50mV and an encapsulation efficiency (%EE) of 96.23±1.16%.","Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27789365/),mv,-,23796,DB00445,Epirubicin
,27789365,zeta potential,"The PSA-BS18 modified liposomal epirubicin (EPI-SL), had a particle size of 133.63±0.92nm, a zeta potential of -26.23±1.50mV and an encapsulation efficiency (%EE) of 96.23±1.16%.","Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27789365/),mv,26.23,23797,DB00445,Epirubicin
,27789365,encapsulation efficiency (%EE),"The PSA-BS18 modified liposomal epirubicin (EPI-SL), had a particle size of 133.63±0.92nm, a zeta potential of -26.23±1.50mV and an encapsulation efficiency (%EE) of 96.23±1.16%.","Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27789365/),%,96.23,23798,DB00445,Epirubicin
,8070217,half-life,"Epirubicin pharmacokinetics may be described by a 3-compartment model, with median half-life values of 3.2 minutes, 1.2 and 32 hours for each phase.",Clinical pharmacokinetics of epirubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070217/),min,3.2,31951,DB00445,Epirubicin
,8070217,half-life,"Epirubicin pharmacokinetics may be described by a 3-compartment model, with median half-life values of 3.2 minutes, 1.2 and 32 hours for each phase.",Clinical pharmacokinetics of epirubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070217/),h,1.2,31952,DB00445,Epirubicin
,8070217,half-life,"Epirubicin pharmacokinetics may be described by a 3-compartment model, with median half-life values of 3.2 minutes, 1.2 and 32 hours for each phase.",Clinical pharmacokinetics of epirubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070217/),h,32,31953,DB00445,Epirubicin
,8070217,Total plasma clearance,Total plasma clearance is 46 L/h/m2 and volume of distribution at steady-state is 1000 L/m2.,Clinical pharmacokinetics of epirubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070217/),[l] / [h·m2],46,31954,DB00445,Epirubicin
,8070217,volume of distribution at steady-state,Total plasma clearance is 46 L/h/m2 and volume of distribution at steady-state is 1000 L/m2.,Clinical pharmacokinetics of epirubicin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070217/),[l] / [m2],1000,31955,DB00445,Epirubicin
,6141919,limit of,"The limit of detection for 4'-epidoxorubicin and 4'-epidoxorubicinol was 1 ng/injection, and concentrations as low as 5 ng/ml could be analyzed in plasma and urine.",Sensitive and specific determination of the new anthracycline analog 4'-epidoxorubicin and its metabolites by high pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6141919/),[ng] / [injection],1,32217,DB00445,Epirubicin
,3165708,maximal tolerated oral dose,The maximal tolerated oral dose of idarubicin was 40 mg/m2 per day.,Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165708/),,40,35004,DB00445,Epirubicin
,3165708,terminal plasma half-life,"The medium terminal plasma half-life of idarubicin was 9.2 h (range, 6.4-25.5 h).",Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165708/),h,9.2,35005,DB00445,Epirubicin
,3165708,concentration,"Among the five patients with acute nonlymphoblastic leukemia whose cells were tested for drug sensitivity in vitro, the idarubicin concentration resulting in 50% inhibition (IC50) of cluster and colony formation ranged from 1.6 x 10(-10) M to 5 x 10(-7) M.",Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165708/),M,1.6 x 10(-10),35006,DB00445,Epirubicin
,3165708,50% inhibition (IC50),"Among the five patients with acute nonlymphoblastic leukemia whose cells were tested for drug sensitivity in vitro, the idarubicin concentration resulting in 50% inhibition (IC50) of cluster and colony formation ranged from 1.6 x 10(-10) M to 5 x 10(-7) M.",Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165708/),M,1.6 x 10(-10),35007,DB00445,Epirubicin
,3165708,50% inhibition (IC50),"Among the five patients with acute nonlymphoblastic leukemia whose cells were tested for drug sensitivity in vitro, the idarubicin concentration resulting in 50% inhibition (IC50) of cluster and colony formation ranged from 1.6 x 10(-10) M to 5 x 10(-7) M.",Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3165708/),M,5 x 10(-7),35008,DB00445,Epirubicin
,18269776,time to progression,"Median time to progression was 5.3 months (95% CI, 3.1-8.9 months), and median time to treatment failure was 3.5 months (95% CI, 2.6-5.9 months).",Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18269776/),month,5.3,37883,DB00445,Epirubicin
,18269776,time to treatment failure,"Median time to progression was 5.3 months (95% CI, 3.1-8.9 months), and median time to treatment failure was 3.5 months (95% CI, 2.6-5.9 months).",Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18269776/),month,3.5,37884,DB00445,Epirubicin
,7710452,gamma-HL,"A statistical significant influence in regard to the terminal elimination half-life (gamma-HL) and the total clearance (CLtot) was found, indicating a reduction of gamma-HL from 18.18 +/- 16.7 for EPR to 8.47 +/- 8.67 h for EPR+IFN and a reduction of the total clearance from 72.33 +/- 55.4 ml/min for EPR to 48.41 +/- 12.7 ml/min for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),h,18.18,39426,DB00445,Epirubicin
,7710452,gamma-HL,"A statistical significant influence in regard to the terminal elimination half-life (gamma-HL) and the total clearance (CLtot) was found, indicating a reduction of gamma-HL from 18.18 +/- 16.7 for EPR to 8.47 +/- 8.67 h for EPR+IFN and a reduction of the total clearance from 72.33 +/- 55.4 ml/min for EPR to 48.41 +/- 12.7 ml/min for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),h,8.47,39427,DB00445,Epirubicin
,7710452,total clearance,"A statistical significant influence in regard to the terminal elimination half-life (gamma-HL) and the total clearance (CLtot) was found, indicating a reduction of gamma-HL from 18.18 +/- 16.7 for EPR to 8.47 +/- 8.67 h for EPR+IFN and a reduction of the total clearance from 72.33 +/- 55.4 ml/min for EPR to 48.41 +/- 12.7 ml/min for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),[ml] / [min],72.33,39428,DB00445,Epirubicin
,7710452,total clearance,"A statistical significant influence in regard to the terminal elimination half-life (gamma-HL) and the total clearance (CLtot) was found, indicating a reduction of gamma-HL from 18.18 +/- 16.7 for EPR to 8.47 +/- 8.67 h for EPR+IFN and a reduction of the total clearance from 72.33 +/- 55.4 ml/min for EPR to 48.41 +/- 12.7 ml/min for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),[ml] / [min],48.41,39429,DB00445,Epirubicin
,7710452,area under the concentration-time curve (AUC,"The area under the concentration-time curve (AUC, according to the 3-compartment model) increases under the influence of IFN from 2004 +/- 1105 ng/ml.h for EPR up to 2582 +/- 1024 ng/ml.h for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),[ng] / [h·ml],2004,39430,DB00445,Epirubicin
,7710452,area under the concentration-time curve (AUC,"The area under the concentration-time curve (AUC, according to the 3-compartment model) increases under the influence of IFN from 2004 +/- 1105 ng/ml.h for EPR up to 2582 +/- 1024 ng/ml.h for EPR+IFN.",Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710452/),[ng] / [h·ml],2582,39431,DB00445,Epirubicin
,11688520,overall response rate,"The overall response rate to GET was 92% (95% CI, 77.53%-98.25%); CR 31% and PR 61%.",Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11688520/),%,92,40254,DB00445,Epirubicin
,11688520,overall response rate,"After six courses of GET, 25 patients received HDCT, leading to an overall response rate of 96% with 58% CR.",Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11688520/),%,96,40255,DB00445,Epirubicin
,11688520,progression free survival,"Median progression free survival is 21 months, while median overall survival has not yet been reached.",Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11688520/),month,21,40256,DB00445,Epirubicin
,3463434,Biliary clearance,"Biliary clearance of epiDX (32.5, 8.1 and 21.6 l/h) is higher than renal clearance (15.2, 3.3 and 9.41 l/h).",Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463434/),[l] / [h],32.5,40362,DB00445,Epirubicin
,3463434,Biliary clearance,"Biliary clearance of epiDX (32.5, 8.1 and 21.6 l/h) is higher than renal clearance (15.2, 3.3 and 9.41 l/h).",Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463434/),[l] / [h],8.1,40363,DB00445,Epirubicin
,3463434,Biliary clearance,"Biliary clearance of epiDX (32.5, 8.1 and 21.6 l/h) is higher than renal clearance (15.2, 3.3 and 9.41 l/h).",Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463434/),[l] / [h],21.6,40364,DB00445,Epirubicin
,3463434,renal clearance,"Biliary clearance of epiDX (32.5, 8.1 and 21.6 l/h) is higher than renal clearance (15.2, 3.3 and 9.41 l/h).",Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463434/),[l] / [h],15.2,40365,DB00445,Epirubicin
,3463434,renal clearance,"Biliary clearance of epiDX (32.5, 8.1 and 21.6 l/h) is higher than renal clearance (15.2, 3.3 and 9.41 l/h).",Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463434/),[l] / [h],3.3,40366,DB00445,Epirubicin
,3463434,renal clearance,"Biliary clearance of epiDX (32.5, 8.1 and 21.6 l/h) is higher than renal clearance (15.2, 3.3 and 9.41 l/h).",Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3463434/),[l] / [h],9.41,40367,DB00445,Epirubicin
,11583191,MTD,At the second step (75 mg/m2 of epirubicin) the MTD of docetaxel was 80 mg/m2.,Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583191/),[mg] / [m2],80,43811,DB00445,Epirubicin
,11583191,Overall response rate,"Overall response rate was 73% in 42 out of 58 patients, with no apparent epirubicin dose-related effect.",Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583191/),%,73,43812,DB00445,Epirubicin
,10561171,AUC,"The EOL AUC after paclitaxel treatment (1,521 +/- 150 ng/mL*h) was significantly higher (P <.01) than the corresponding values after epirubicin administered either as a single agent (692 +/- 46 ng/mL*h) or in combination with docetaxel (848 +/- 237 ng/mL*h).",Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561171/),[ng] / [h·ml],"1,521",46568,DB00445,Epirubicin
,10561171,AUC,"The EOL AUC after paclitaxel treatment (1,521 +/- 150 ng/mL*h) was significantly higher (P <.01) than the corresponding values after epirubicin administered either as a single agent (692 +/- 46 ng/mL*h) or in combination with docetaxel (848 +/- 237 ng/mL*h).",Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561171/),[ng] / [h·ml],692,46569,DB00445,Epirubicin
,10561171,AUC,"The EOL AUC after paclitaxel treatment (1,521 +/- 150 ng/mL*h) was significantly higher (P <.01) than the corresponding values after epirubicin administered either as a single agent (692 +/- 46 ng/mL*h) or in combination with docetaxel (848 +/- 237 ng/mL*h).",Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561171/),[ng] / [h·ml],848,46570,DB00445,Epirubicin
,21351514,extract recovery,"The average extract recovery was 89.3% and 92.1%, respectively.",[Pharmacokinetics of epirubicin hydrochloride long-circulating thermosensitive liposomes in rat plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351514/),%,89.3,48249,DB00445,Epirubicin
,21351514,extract recovery,"The average extract recovery was 89.3% and 92.1%, respectively.",[Pharmacokinetics of epirubicin hydrochloride long-circulating thermosensitive liposomes in rat plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351514/),%,92.1,48250,DB00445,Epirubicin
,9626462,trough,"The median trough dexverapamil plus norverapamil level on day 3 was 1110 ng/ml (range, 186-3385 ng/ml), and the median peak level was 2164 ng/ml (range, 964-8382 ng/ml).",Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626462/),[ng] / [ml],1110,50015,DB00445,Epirubicin
,9626462,peak level,"The median trough dexverapamil plus norverapamil level on day 3 was 1110 ng/ml (range, 186-3385 ng/ml), and the median peak level was 2164 ng/ml (range, 964-8382 ng/ml).",Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626462/),[ng] / [ml],2164,50016,DB00445,Epirubicin
,26812610,hydrodynamic particle size,"Average hydrodynamic particle size of EPI-PNPs and EPI-MNPs was found 248.63 ± 12.36 and 254.23 ± 15.16 nm, respectively.",Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26812610/),nm,248.63,50518,DB00445,Epirubicin
,26812610,hydrodynamic particle size,"Average hydrodynamic particle size of EPI-PNPs and EPI-MNPs was found 248.63 ± 12.36 and 254.23 ± 15.16 nm, respectively.",Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26812610/),nm,254.23,50519,DB00445,Epirubicin
,8431970,Maximal concentrations,"Maximal concentrations of VPL and nor-VPL reached 705 +/- 473 and 308 +/- 122 ng/ml, respectively, with the steady-state concentrations being 265 +/- 42 ng/ml for VPL and 180 +/- 12 ng/ml for nor-VPL.",Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431970/),[ng] / [ml],705,51952,DB00445,Epirubicin
,8431970,Maximal concentrations,"Maximal concentrations of VPL and nor-VPL reached 705 +/- 473 and 308 +/- 122 ng/ml, respectively, with the steady-state concentrations being 265 +/- 42 ng/ml for VPL and 180 +/- 12 ng/ml for nor-VPL.",Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431970/),[ng] / [ml],308,51953,DB00445,Epirubicin
,8431970,steady-state concentrations,"Maximal concentrations of VPL and nor-VPL reached 705 +/- 473 and 308 +/- 122 ng/ml, respectively, with the steady-state concentrations being 265 +/- 42 ng/ml for VPL and 180 +/- 12 ng/ml for nor-VPL.",Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431970/),[ng] / [ml],265,51954,DB00445,Epirubicin
,8431970,steady-state concentrations,"Maximal concentrations of VPL and nor-VPL reached 705 +/- 473 and 308 +/- 122 ng/ml, respectively, with the steady-state concentrations being 265 +/- 42 ng/ml for VPL and 180 +/- 12 ng/ml for nor-VPL.",Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431970/),[ng] / [ml],180,51955,DB00445,Epirubicin
,3457647,Peak levels,Plasma levels of the reduced metabolite DMDRol were higher than those of the parent compound: Peak levels were 4-10 ng/ml for DMDR and 15-40 ng/ml for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),[ng] / [ml],4-10,51995,DB00445,Epirubicin
,3457647,Peak levels,Plasma levels of the reduced metabolite DMDRol were higher than those of the parent compound: Peak levels were 4-10 ng/ml for DMDR and 15-40 ng/ml for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),[ng] / [ml],15-40,51996,DB00445,Epirubicin
,3457647,area under the time-concentration curve (AUC),"The dose-corrected area under the time-concentration curve (AUC) was consequently higher for DMDRol (12.3-74.7, mean 32.6 vs 2.4-7.4, mean 4.6 ng/ml.mg for DMDR).",Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),[ng] / [mg·ml],32.6,51997,DB00445,Epirubicin
,3457647,area under the time-concentration curve (AUC),"The dose-corrected area under the time-concentration curve (AUC) was consequently higher for DMDRol (12.3-74.7, mean 32.6 vs 2.4-7.4, mean 4.6 ng/ml.mg for DMDR).",Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),[ng] / [mg·ml],4.6,51998,DB00445,Epirubicin
,3457647,Apparent plasma terminal half-lives,Apparent plasma terminal half-lives after the last dose administered were in the range of 13-36 (mean 23.7) h for DMDR and 30-81 (mean 58.9) h for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),h,13-36,51999,DB00445,Epirubicin
,3457647,Apparent plasma terminal half-lives,Apparent plasma terminal half-lives after the last dose administered were in the range of 13-36 (mean 23.7) h for DMDR and 30-81 (mean 58.9) h for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),h,23.7,52000,DB00445,Epirubicin
,3457647,Apparent plasma terminal half-lives,Apparent plasma terminal half-lives after the last dose administered were in the range of 13-36 (mean 23.7) h for DMDR and 30-81 (mean 58.9) h for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),h,30-81,52001,DB00445,Epirubicin
,3457647,Apparent plasma terminal half-lives,Apparent plasma terminal half-lives after the last dose administered were in the range of 13-36 (mean 23.7) h for DMDR and 30-81 (mean 58.9) h for DMDRol.,Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3457647/),h,58.9,52002,DB00445,Epirubicin
,28054329,objective response rate,"Partial response was observed in one patient with breast cancer treated at 100 mg/m2, yielding an objective response rate of 5% (1/19).",A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28054329/),%,5,54338,DB00445,Epirubicin
,10550567,Clearance (CL),"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],3. 57,55584,DB00445,Epirubicin
,10550567,intercompartmental clearances,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55585,DB00445,Epirubicin
,10550567,intercompartmental clearances,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55586,DB00445,Epirubicin
,10550567,intercompartmental clearances,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55587,DB00445,Epirubicin
,10550567,intercompartmental clearances,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],3.67,55588,DB00445,Epirubicin
,10550567,Q2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55589,DB00445,Epirubicin
,10550567,Q2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55590,DB00445,Epirubicin
,10550567,Q2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55591,DB00445,Epirubicin
,10550567,Q3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55592,DB00445,Epirubicin
,10550567,Q3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55593,DB00445,Epirubicin
,10550567,Q3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55594,DB00445,Epirubicin
,10550567,central (,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55595,DB00445,Epirubicin
,10550567,central (,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55596,DB00445,Epirubicin
,10550567,V1,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55597,DB00445,Epirubicin
,10550567,V1,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55598,DB00445,Epirubicin
,10550567,V1,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55599,DB00445,Epirubicin
,10550567,V2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55600,DB00445,Epirubicin
,10550567,V2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55601,DB00445,Epirubicin
,10550567,V2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55602,DB00445,Epirubicin
,10550567,V2,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],3.67,55603,DB00445,Epirubicin
,10550567,V3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],5.01,55604,DB00445,Epirubicin
,10550567,V3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],12.48,55605,DB00445,Epirubicin
,10550567,V3,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.805,55606,DB00445,Epirubicin
,10550567,volumes of distribution,"Clearance (CL), intercompartmental clearances (Q2 and Q3), central (V1) and peripheral (V2 and V3) volumes of distribution were estimated as 3. 57 l/h per kg, 5.01 l/h per kg, 12.48 l/h per kg, 0.805 l/kg, 3.67 l/kg and 158 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],158,55607,DB00445,Epirubicin
,10550567,CL,"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],7.3,55608,DB00445,Epirubicin
,10550567,intercompartmental clearance (Q),"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],4. 6,55609,DB00445,Epirubicin
,10550567,intercompartmental clearance (Q),"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.69,55610,DB00445,Epirubicin
,10550567,V1,"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [h·kg],4. 6,55611,DB00445,Epirubicin
,10550567,V1,"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],0.69,55612,DB00445,Epirubicin
,10550567,V2,"CL, intercompartmental clearance (Q), V1 and V2 for DTX were estimated as 7.3 l/h per kg, 4. 6 l/h per kg, 0.69 l/kg and 2.6 l/kg, respectively.",The pharmacokinetics of epirubicin and docetaxel in combination in rats. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10550567/),[l] / [kg],2.6,55613,DB00445,Epirubicin
,7546045,t(1/2),"Within the first 15 min after administration, EPR was distributed from the central compartment distinctly faster in compare to the control, when QUI was preadministered (t(1/2) = 6 min for the control group and t(1/2) = 3 min with QUI; -46%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),min,6,56863,DB00445,Epirubicin
,7546045,t(1/2),"Within the first 15 min after administration, EPR was distributed from the central compartment distinctly faster in compare to the control, when QUI was preadministered (t(1/2) = 6 min for the control group and t(1/2) = 3 min with QUI; -46%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),min,3,56864,DB00445,Epirubicin
,7546045,Half-life of elimination,Half-life of elimination was 0.5 h for the control group and 8.6 h for the QUI group (-10%).,Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),h,0.5,56865,DB00445,Epirubicin
,7546045,Half-life of elimination,Half-life of elimination was 0.5 h for the control group and 8.6 h for the QUI group (-10%).,Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),h,8.6,56866,DB00445,Epirubicin
,7546045,initial serum concentration (co),"The mean initial serum concentration (co) was reduced significantly by QUI from 7359 +/- 506 ng/ml to 4351 +/- 1682 ng/ml (-42%, p < 0.005).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ng] / [ml],7359,56867,DB00445,Epirubicin
,7546045,initial serum concentration (co),"The mean initial serum concentration (co) was reduced significantly by QUI from 7359 +/- 506 ng/ml to 4351 +/- 1682 ng/ml (-42%, p < 0.005).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ng] / [ml],4351,56868,DB00445,Epirubicin
,7546045,serum bioavailability,"Furthermore, QUI caused a reduction of the serum bioavailability of EPR (expressed as AUC(o-24)-values) from 3404 +/- 1008 ng/ml x h to 2359 +/- 1073 ng/ml x h (-31%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ng] / [h·ml],3404,56869,DB00445,Epirubicin
,7546045,serum bioavailability,"Furthermore, QUI caused a reduction of the serum bioavailability of EPR (expressed as AUC(o-24)-values) from 3404 +/- 1008 ng/ml x h to 2359 +/- 1073 ng/ml x h (-31%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[h·ml·ng] / [-],2359,56870,DB00445,Epirubicin
,7546045,AUC(o-24),"Furthermore, QUI caused a reduction of the serum bioavailability of EPR (expressed as AUC(o-24)-values) from 3404 +/- 1008 ng/ml x h to 2359 +/- 1073 ng/ml x h (-31%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ng] / [h·ml],3404,56871,DB00445,Epirubicin
,7546045,AUC(o-24),"Furthermore, QUI caused a reduction of the serum bioavailability of EPR (expressed as AUC(o-24)-values) from 3404 +/- 1008 ng/ml x h to 2359 +/- 1073 ng/ml x h (-31%, p < 0.05).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[h·ml·ng] / [-],2359,56872,DB00445,Epirubicin
,7546045,total body clearance,"Vd and Vdbeta were increased at about 90% and the mean total body clearance was accelerated from 45.3 to 1487 ml/min, but due to the large standard deviations the calculated difference for these parameters was not statistically significant.",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),[ml] / [min],45,56873,DB00445,Epirubicin
,7546045,k(rbc),"In the observed time interval of 24 h, the red blood cell coefficient of distribution k(rbc) of EPR was lower if QUI was coadministered (k(rbc) = 1.25 +/- 0.12 for the control group k(rbc) = 1.15 +/- 0.13 under QUI; p < 0.04).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),,1.25,56874,DB00445,Epirubicin
,7546045,k(rbc),"In the observed time interval of 24 h, the red blood cell coefficient of distribution k(rbc) of EPR was lower if QUI was coadministered (k(rbc) = 1.25 +/- 0.12 for the control group k(rbc) = 1.15 +/- 0.13 under QUI; p < 0.04).",Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7546045/),,1.15,56875,DB00445,Epirubicin
,1530304,hepatic extraction,"The hepatic extraction calculated from the areas under the plasma concentration time curve of both administrations was 40% in ADM, 60% in ERB, and 0% in MMC.",[A pharmacokinetic study of intra-arterial chemotherapy for prophylactic treatment of liver metastasis after hepatectomy for liver cancer]. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530304/),%,40,57794,DB00445,Epirubicin
,1530304,hepatic extraction,"The hepatic extraction calculated from the areas under the plasma concentration time curve of both administrations was 40% in ADM, 60% in ERB, and 0% in MMC.",[A pharmacokinetic study of intra-arterial chemotherapy for prophylactic treatment of liver metastasis after hepatectomy for liver cancer]. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530304/),%,60,57795,DB00445,Epirubicin
,1530304,hepatic extraction,"The hepatic extraction calculated from the areas under the plasma concentration time curve of both administrations was 40% in ADM, 60% in ERB, and 0% in MMC.",[A pharmacokinetic study of intra-arterial chemotherapy for prophylactic treatment of liver metastasis after hepatectomy for liver cancer]. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530304/),%,0,57796,DB00445,Epirubicin
,2758564,terminal plasma half-life,Plasma levels of the compound were fitted to a three-compartment open model; a triexponential decrease in plasma concentrations with a long terminal plasma half-life (44.8 +/- 21.2 h) was observed in 27 patients.,Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),h,44.8,58272,DB00445,Epirubicin
,2758564,serum,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[ng] / [ml],7.67,58273,DB00445,Epirubicin
,2758564,AUC,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[ng] / [ml],7.67,58274,DB00445,Epirubicin
,2758564,plasma clearance,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[h·ng] / [ml],"4,002",58275,DB00445,Epirubicin
,2758564,plasma clearance,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[l] / [h·m2],26.6,58276,DB00445,Epirubicin
,2758564,plasma clearance,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[ng] / [ml],4.96,58277,DB00445,Epirubicin
,2758564,plasma clearance,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[h·ng] / [ml],1.88,58278,DB00445,Epirubicin
,2758564,terminal elimination rate constant,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[l] / [h],0.009,58279,DB00445,Epirubicin
,2758564,terminal elimination rate constant,"The respective mean (+/- SD) serum concentration at 72 h and the AUC, plasma clearance, and terminal elimination rate constant in complete responders were 7.67 +/- 1.98 ng/ml, 4,002 +/- 3,080 ng.h/ml, 26.6 +/- 12.9 l/h.m2, and 0.009 +/- 0.007 l/h, whereas those in nonresponders were 4.96 +/- 1.8 ng/ml, 1.88 +/- 652.8 ng.h/ml, 44.4 +/- 15 l/h.m2, and 0.017 +/- 0.006 l/h, respectively; these differences were significant (P less than 0.05).",Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758564/),[l] / [h],0.017,58280,DB00445,Epirubicin
,9796961,area under the concentration versus time curve (AUC),"The plasma area under the concentration versus time curve (AUC) of doxorubicin increased from 1448 +/- 350 to 1786 +/- 264 ng/ml x h (P = 0.02) in the presence of cremophor, whereas the AUC of doxorubicinol increased from 252 +/- 104 to 486 +/- 107 ng/ml x h (P = 0.02).",Phase I trial of cremophor EL with bolus doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796961/),[ng] / [h·ml],1448,59876,DB00445,Epirubicin
,9796961,area under the concentration versus time curve (AUC),"The plasma area under the concentration versus time curve (AUC) of doxorubicin increased from 1448 +/- 350 to 1786 +/- 264 ng/ml x h (P = 0.02) in the presence of cremophor, whereas the AUC of doxorubicinol increased from 252 +/- 104 to 486 +/- 107 ng/ml x h (P = 0.02).",Phase I trial of cremophor EL with bolus doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796961/),[ng] / [h·ml],1786,59877,DB00445,Epirubicin
,9796961,AUC,"The plasma area under the concentration versus time curve (AUC) of doxorubicin increased from 1448 +/- 350 to 1786 +/- 264 ng/ml x h (P = 0.02) in the presence of cremophor, whereas the AUC of doxorubicinol increased from 252 +/- 104 to 486 +/- 107 ng/ml x h (P = 0.02).",Phase I trial of cremophor EL with bolus doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796961/),[ng] / [h·ml],252,59878,DB00445,Epirubicin
,9796961,AUC,"The plasma area under the concentration versus time curve (AUC) of doxorubicin increased from 1448 +/- 350 to 1786 +/- 264 ng/ml x h (P = 0.02) in the presence of cremophor, whereas the AUC of doxorubicinol increased from 252 +/- 104 to 486 +/- 107 ng/ml x h (P = 0.02).",Phase I trial of cremophor EL with bolus doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796961/),[ng] / [h·ml],486,59879,DB00445,Epirubicin
,12628836,areas under the concentration-time curve (AUCs),We first identified target areas under the concentration-time curve (AUCs) of 2400 and 1600 ng/ml.h from pharmacokinetic studies in 15 women with normal liver tests.,Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12628836/),[ng] / [h·ml],2400,65723,DB00445,Epirubicin
,12628836,areas under the concentration-time curve (AUCs),We first identified target areas under the concentration-time curve (AUCs) of 2400 and 1600 ng/ml.h from pharmacokinetic studies in 15 women with normal liver tests.,Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12628836/),[ng] / [h·ml],1600,65724,DB00445,Epirubicin
,12628836,AUCs,"The median AUCs were 2444 and 1608 ng/ml.h, close to the high and low target AUCs, respectively.",Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12628836/),[ng] / [h·ml],2444,65725,DB00445,Epirubicin
,12628836,AUCs,"The median AUCs were 2444 and 1608 ng/ml.h, close to the high and low target AUCs, respectively.",Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12628836/),[ng] / [h·ml],1608,65726,DB00445,Epirubicin
,30042075,OS times,"Median OS times in the stable and unstable emulsion arms were 17.7 and 19.2 months, respectively (P = .81).",Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma: Results of a Single-Center Double-Blind Prospective Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30042075/),month,17.7,65868,DB00445,Epirubicin
,30042075,OS times,"Median OS times in the stable and unstable emulsion arms were 17.7 and 19.2 months, respectively (P = .81).",Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma: Results of a Single-Center Double-Blind Prospective Randomized Controlled Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30042075/),month,19.2,65869,DB00445,Epirubicin
,12881383,area under the plasma concentration-time curve (AUC(0-24 h)),The area under the plasma concentration-time curve (AUC(0-24 h)) was 1230 +/- 318 [mean +/- standard deviation (SD)] at the first cycle and 1287 +/- 385 h.,Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),,1230,66532,DB00445,Epirubicin
,12881383,area under the plasma concentration-time curve (AUC(0-24 h)),The area under the plasma concentration-time curve (AUC(0-24 h)) was 1230 +/- 318 [mean +/- standard deviation (SD)] at the first cycle and 1287 +/- 385 h.,Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),,1287,66533,DB00445,Epirubicin
,12881383,maximum plasma concentration (C(max)),"The mean (+/-SD) maximum plasma concentration (C(max)) and the terminal elimination half-life at the first cycle (1303 +/- 490 micro g/l and 12.5 +/- 3.1 h, respectively) were similar to those obtained at the sixth cycle (1229 +/- 580 micro g/l and 11.5 +/- 2.9 h, respectively).",Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),[μg] / [l],1303,66534,DB00445,Epirubicin
,12881383,maximum plasma concentration (C(max)),"The mean (+/-SD) maximum plasma concentration (C(max)) and the terminal elimination half-life at the first cycle (1303 +/- 490 micro g/l and 12.5 +/- 3.1 h, respectively) were similar to those obtained at the sixth cycle (1229 +/- 580 micro g/l and 11.5 +/- 2.9 h, respectively).",Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),[μg] / [l],1229,66535,DB00445,Epirubicin
,12881383,terminal elimination half-life,"The mean (+/-SD) maximum plasma concentration (C(max)) and the terminal elimination half-life at the first cycle (1303 +/- 490 micro g/l and 12.5 +/- 3.1 h, respectively) were similar to those obtained at the sixth cycle (1229 +/- 580 micro g/l and 11.5 +/- 2.9 h, respectively).",Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),h,12.5,66536,DB00445,Epirubicin
,12881383,terminal elimination half-life,"The mean (+/-SD) maximum plasma concentration (C(max)) and the terminal elimination half-life at the first cycle (1303 +/- 490 micro g/l and 12.5 +/- 3.1 h, respectively) were similar to those obtained at the sixth cycle (1229 +/- 580 micro g/l and 11.5 +/- 2.9 h, respectively).",Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12881383/),h,11.5,66537,DB00445,Epirubicin
,3162516,cumulative urinary excretion,"The cumulative urinary excretion appeared to be 10.5% for EPI and its metabolites, and 6.9% for DOX and its metabolite.",Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162516/),%,10.5,67145,DB00445,Epirubicin
,3162516,cumulative urinary excretion,"The cumulative urinary excretion appeared to be 10.5% for EPI and its metabolites, and 6.9% for DOX and its metabolite.",Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162516/),%,6.9,67146,DB00445,Epirubicin
over,1568796,distribution half-life,"In contrast, when administered in the S-EPI formulation, the distribution half-life of the drug was over 22 hr.",Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568796/),h,22,68107,DB00445,Epirubicin
,1568796,clearance,"S-EPI also exhibited a reduced clearance compared to F-EPI, from 111 to less than 1.0 ml/hr.",Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568796/),[ml] / [h],111,68108,DB00445,Epirubicin
less,1568796,clearance,"S-EPI also exhibited a reduced clearance compared to F-EPI, from 111 to less than 1.0 ml/hr.",Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1568796/),[ml] / [h],1.0,68109,DB00445,Epirubicin
,3162849,t/2 alpha,Half-lives (t/2) of the three decay phases were longer for DX (t/2 alpha: 4.8 vs. 3 min; t/2 beta 2.57 h vs. 1.09 h; t/2 gamma 48.4 vs. 31.2 h).,Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),min,4.8,68595,DB00445,Epirubicin
,3162849,t/2 alpha,Half-lives (t/2) of the three decay phases were longer for DX (t/2 alpha: 4.8 vs. 3 min; t/2 beta 2.57 h vs. 1.09 h; t/2 gamma 48.4 vs. 31.2 h).,Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),min,3,68596,DB00445,Epirubicin
,3162849,t/2 beta,Half-lives (t/2) of the three decay phases were longer for DX (t/2 alpha: 4.8 vs. 3 min; t/2 beta 2.57 h vs. 1.09 h; t/2 gamma 48.4 vs. 31.2 h).,Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,2.57,68597,DB00445,Epirubicin
,3162849,t/2 beta,Half-lives (t/2) of the three decay phases were longer for DX (t/2 alpha: 4.8 vs. 3 min; t/2 beta 2.57 h vs. 1.09 h; t/2 gamma 48.4 vs. 31.2 h).,Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,1.09,68598,DB00445,Epirubicin
,3162849,t/2 gamma,Half-lives (t/2) of the three decay phases were longer for DX (t/2 alpha: 4.8 vs. 3 min; t/2 beta 2.57 h vs. 1.09 h; t/2 gamma 48.4 vs. 31.2 h).,Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,48.4,68599,DB00445,Epirubicin
,3162849,t/2 gamma,Half-lives (t/2) of the three decay phases were longer for DX (t/2 alpha: 4.8 vs. 3 min; t/2 beta 2.57 h vs. 1.09 h; t/2 gamma 48.4 vs. 31.2 h).,Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,31.2,68600,DB00445,Epirubicin
,3162849,PlCl,"According to a model-independent analysis, the different plasma disposition kinetics of the two compounds appears to be related to a higher plasma clearance (PlCl) and to a lower mean residence time (MRT) of epiDX (PlCl: 75.0 l/h, range: 35.6-133.4 l/h; MRT: 31.6 h, range: 7.0-41.5 h;) compared to DX (PlCl: 56.8 l/h, range: 24.4-119.5; MRT: 45.6 h, range: 26.0-83.1 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [h],75.0,68601,DB00445,Epirubicin
,3162849,MRT,"According to a model-independent analysis, the different plasma disposition kinetics of the two compounds appears to be related to a higher plasma clearance (PlCl) and to a lower mean residence time (MRT) of epiDX (PlCl: 75.0 l/h, range: 35.6-133.4 l/h; MRT: 31.6 h, range: 7.0-41.5 h;) compared to DX (PlCl: 56.8 l/h, range: 24.4-119.5; MRT: 45.6 h, range: 26.0-83.1 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,31.6,68602,DB00445,Epirubicin
,3162849,PlCl,"According to a model-independent analysis, the different plasma disposition kinetics of the two compounds appears to be related to a higher plasma clearance (PlCl) and to a lower mean residence time (MRT) of epiDX (PlCl: 75.0 l/h, range: 35.6-133.4 l/h; MRT: 31.6 h, range: 7.0-41.5 h;) compared to DX (PlCl: 56.8 l/h, range: 24.4-119.5; MRT: 45.6 h, range: 26.0-83.1 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [h],56.8,68603,DB00445,Epirubicin
,3162849,MRT,"According to a model-independent analysis, the different plasma disposition kinetics of the two compounds appears to be related to a higher plasma clearance (PlCl) and to a lower mean residence time (MRT) of epiDX (PlCl: 75.0 l/h, range: 35.6-133.4 l/h; MRT: 31.6 h, range: 7.0-41.5 h;) compared to DX (PlCl: 56.8 l/h, range: 24.4-119.5; MRT: 45.6 h, range: 26.0-83.1 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,45.6,68604,DB00445,Epirubicin
,3162849,volume of distribution at steady state (Vss),"No statistically significant differences could be detected for the volume of distribution at steady state (Vss) (epiDX, 31.8 l/kg; DX, 33.3 l/kg).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [kg],31.8,68605,DB00445,Epirubicin
,3162849,volume of distribution at steady state (Vss),"No statistically significant differences could be detected for the volume of distribution at steady state (Vss) (epiDX, 31.8 l/kg; DX, 33.3 l/kg).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [kg],33.3,68606,DB00445,Epirubicin
,3162849,renal clearance,"A comparable renal clearance was calculated for DX (4.7 l/h, range 1.4-7.0 l/h) and epiDX (4.4 l/h, range 1.7-7.0 l/h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [h],4.7,68607,DB00445,Epirubicin
,3162849,renal clearance,"A comparable renal clearance was calculated for DX (4.7 l/h, range 1.4-7.0 l/h) and epiDX (4.4 l/h, range 1.7-7.0 l/h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [h],4.4,68608,DB00445,Epirubicin
,3162849,PlCl,"The elimination of both drugs was significantly impaired in this patient; nevertheless, elimination of epiDX was still more efficient and faster than that of DX (PlCl: 35.6 vs. 24.4 l/h; MRT: 39.0 vs. 83.1 h; t/2 gamma: 47 vs. 74 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [h],35.6,68609,DB00445,Epirubicin
,3162849,PlCl,"The elimination of both drugs was significantly impaired in this patient; nevertheless, elimination of epiDX was still more efficient and faster than that of DX (PlCl: 35.6 vs. 24.4 l/h; MRT: 39.0 vs. 83.1 h; t/2 gamma: 47 vs. 74 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),[l] / [h],24.4,68610,DB00445,Epirubicin
,3162849,MRT,"The elimination of both drugs was significantly impaired in this patient; nevertheless, elimination of epiDX was still more efficient and faster than that of DX (PlCl: 35.6 vs. 24.4 l/h; MRT: 39.0 vs. 83.1 h; t/2 gamma: 47 vs. 74 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,39.0,68611,DB00445,Epirubicin
,3162849,MRT,"The elimination of both drugs was significantly impaired in this patient; nevertheless, elimination of epiDX was still more efficient and faster than that of DX (PlCl: 35.6 vs. 24.4 l/h; MRT: 39.0 vs. 83.1 h; t/2 gamma: 47 vs. 74 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,83.1,68612,DB00445,Epirubicin
,3162849,t/2 gamma,"The elimination of both drugs was significantly impaired in this patient; nevertheless, elimination of epiDX was still more efficient and faster than that of DX (PlCl: 35.6 vs. 24.4 l/h; MRT: 39.0 vs. 83.1 h; t/2 gamma: 47 vs. 74 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,47,68613,DB00445,Epirubicin
,3162849,t/2 gamma,"The elimination of both drugs was significantly impaired in this patient; nevertheless, elimination of epiDX was still more efficient and faster than that of DX (PlCl: 35.6 vs. 24.4 l/h; MRT: 39.0 vs. 83.1 h; t/2 gamma: 47 vs. 74 h).",Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3162849/),h,74,68614,DB00445,Epirubicin
,1829915,steady state plasma concentration,"Bepridil was administered in a continuous 36 h infusion at 22 mg/kg/36 h, with a dose scheme which should result in a steady state plasma concentration of approximately 5 mumol/l, able to reverse anthracycline resistance in vitro.",Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829915/),[μM] / [l],5,74555,DB00445,Epirubicin
,1829915,plasma concentration,"Pharmacokinetic studies demonstrated a median bepridil plasma concentration of 5.3 mumol/l (range 2.6-19.3 mumol/l), at the time of administration of the anthracycline.",Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829915/),[μM] / [l],5.3,74556,DB00445,Epirubicin
,18187954,occurrence probabilities,"Based on CRM calculation, mean DLT occurrence probabilities (90% confidence intervals in parentheses) for levels 2, 3 and 4 were 21% (8-42%), 35% (17-56%) and 56% (38-71%), respectively.",Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18187954/),%,21,77038,DB00445,Epirubicin
,18187954,occurrence probabilities,"Based on CRM calculation, mean DLT occurrence probabilities (90% confidence intervals in parentheses) for levels 2, 3 and 4 were 21% (8-42%), 35% (17-56%) and 56% (38-71%), respectively.",Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18187954/),%,35,77039,DB00445,Epirubicin
,18187954,occurrence probabilities,"Based on CRM calculation, mean DLT occurrence probabilities (90% confidence intervals in parentheses) for levels 2, 3 and 4 were 21% (8-42%), 35% (17-56%) and 56% (38-71%), respectively.",Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18187954/),%,56,77040,DB00445,Epirubicin
,17453364,time to progression,"At median follow-up of 113 months, the median time to progression and median overall survival were 14 and 36 months, respectively.","Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17453364/),month,14,78618,DB00445,Epirubicin
,17453364,overall survival,"At median follow-up of 113 months, the median time to progression and median overall survival were 14 and 36 months, respectively.","Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17453364/),month,36,78619,DB00445,Epirubicin
,21556546,overall response rate,Among 35 evaluable patients there were 2 complete responses and 3 partial responses (PR) for an overall response rate of 14%.,Clinical modulation of epirubicin resistance by lonidamine in patients with advanced soft-tissue sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21556546/),%,14,78859,DB00445,Epirubicin
,21556546,overall survivall,The overall survivall was 11.5 months.,Clinical modulation of epirubicin resistance by lonidamine in patients with advanced soft-tissue sarcomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21556546/),month,11.5,78860,DB00445,Epirubicin
,17907289,response rate,"One patient showed complete response (CR) with disappearance of HCC and PVTT after treatment, and the two patients showed partial response (PR), response rate (CR + PR/All cases 30%).","Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17907289/),%,30,81438,DB00445,Epirubicin
,17907289,survival time,The median survival time after the therapy was 457.2 d.,"Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17907289/),d,457.2,81439,DB00445,Epirubicin
,3282579,elimination half-life,The elimination half-life of epirubicin or esorubicin is similar to that of doxorubicin (30 h) and the elimination half-life of unchanged idarubicin or pirarubicin is shorter (15-20 h).,[Pharmacokinetics of new anthracyclines]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282579/),h,30,83802,DB00445,Epirubicin
,3282579,elimination half-life,The elimination half-life of epirubicin or esorubicin is similar to that of doxorubicin (30 h) and the elimination half-life of unchanged idarubicin or pirarubicin is shorter (15-20 h).,[Pharmacokinetics of new anthracyclines]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3282579/),h,15-20,83803,DB00445,Epirubicin
,7945673,encapsulation rate,The in vitro encapsulation rate in isolated erythrocytes amounts to 52.9 +/- 2.8% and remains constant within the range of studied concentrations (2.5-20 micrograms/ml).,In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,52.9,84025,DB00445,Epirubicin
,7945673,Binding,"Binding to alpha-HSA amounted up to 51.0 +/- 7.10%, to alpha+beta-HSG 79.45 +/- 2.7%, to gamma-HSG 57.1 +/- 2.8%.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,51,84026,DB00445,Epirubicin
,7945673,Binding,"Binding to alpha-HSA amounted up to 51.0 +/- 7.10%, to alpha+beta-HSG 79.45 +/- 2.7%, to gamma-HSG 57.1 +/- 2.8%.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,79.45,84027,DB00445,Epirubicin
,7945673,Binding,"Binding to alpha-HSA amounted up to 51.0 +/- 7.10%, to alpha+beta-HSG 79.45 +/- 2.7%, to gamma-HSG 57.1 +/- 2.8%.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,57.1,84028,DB00445,Epirubicin
,7945673,in vivo-binding rate,"The in vivo-binding rate of EPR, dihydroepirubicin and deoxydoxorubicinone to RBCs after 5 min of injection was 32 +/- 6.96%, 11.6 +/- 3.1% and 10.05 +/- 3.5% respectively, their availability in serum was 42.6 +/- 11.8%, 2.4 +/- 0.4% and 1.2 +/- 0.67% respectively.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,32,84029,DB00445,Epirubicin
,7945673,in vivo-binding rate,"The in vivo-binding rate of EPR, dihydroepirubicin and deoxydoxorubicinone to RBCs after 5 min of injection was 32 +/- 6.96%, 11.6 +/- 3.1% and 10.05 +/- 3.5% respectively, their availability in serum was 42.6 +/- 11.8%, 2.4 +/- 0.4% and 1.2 +/- 0.67% respectively.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,11.6,84030,DB00445,Epirubicin
,7945673,in vivo-binding rate,"The in vivo-binding rate of EPR, dihydroepirubicin and deoxydoxorubicinone to RBCs after 5 min of injection was 32 +/- 6.96%, 11.6 +/- 3.1% and 10.05 +/- 3.5% respectively, their availability in serum was 42.6 +/- 11.8%, 2.4 +/- 0.4% and 1.2 +/- 0.67% respectively.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,10.05,84031,DB00445,Epirubicin
,7945673,availability in serum,"The in vivo-binding rate of EPR, dihydroepirubicin and deoxydoxorubicinone to RBCs after 5 min of injection was 32 +/- 6.96%, 11.6 +/- 3.1% and 10.05 +/- 3.5% respectively, their availability in serum was 42.6 +/- 11.8%, 2.4 +/- 0.4% and 1.2 +/- 0.67% respectively.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,42.6,84032,DB00445,Epirubicin
,7945673,availability in serum,"The in vivo-binding rate of EPR, dihydroepirubicin and deoxydoxorubicinone to RBCs after 5 min of injection was 32 +/- 6.96%, 11.6 +/- 3.1% and 10.05 +/- 3.5% respectively, their availability in serum was 42.6 +/- 11.8%, 2.4 +/- 0.4% and 1.2 +/- 0.67% respectively.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,2.4,84033,DB00445,Epirubicin
,7945673,availability in serum,"The in vivo-binding rate of EPR, dihydroepirubicin and deoxydoxorubicinone to RBCs after 5 min of injection was 32 +/- 6.96%, 11.6 +/- 3.1% and 10.05 +/- 3.5% respectively, their availability in serum was 42.6 +/- 11.8%, 2.4 +/- 0.4% and 1.2 +/- 0.67% respectively.",In vitro and in vivo binding of epirubicin to red blood cells and human plasma proteins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7945673/),%,1.2,84034,DB00445,Epirubicin
,10789596,Cmax ratio Dox/Epi,The Cmax ratio Dox/Epi was 1.39+/-0.19 (mean +/- SD).,A comparative pharmacokinetic study of doxorubicin and 4'-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10789596/),,1.39,84340,DB00445,Epirubicin
,9569055,area under the plasma concentration-time curve (AUC),"In nine intrapatient comparisons, the area under the plasma concentration-time curve (AUC) of epirubicin was significantly reduced by dexverapamil (mean 2968 vs 1901 microg ml[-1] h[-1], P= 0.02).",Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9569055/),[μg] / [h·ml],2968,84831,DB00445,Epirubicin
,9569055,area under the plasma concentration-time curve (AUC),"In nine intrapatient comparisons, the area under the plasma concentration-time curve (AUC) of epirubicin was significantly reduced by dexverapamil (mean 2968 vs 1901 microg ml[-1] h[-1], P= 0.02).",Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9569055/),[μg] / [h·ml],1901,84832,DB00445,Epirubicin
,9569055,trough plasma levels,The mean trough plasma levels of dexverapamil and its major metabolite nor-dexverapamil were 1.2 and 1.5 microM respectively.,Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9569055/),μM,1.2,84833,DB00445,Epirubicin
,9569055,trough plasma levels,The mean trough plasma levels of dexverapamil and its major metabolite nor-dexverapamil were 1.2 and 1.5 microM respectively.,Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9569055/),μM,1.5,84834,DB00445,Epirubicin
,8690750,concentrations,In vivo concentrations of dexniguldipine 5 h after a single oral dose of 30 mg/kg were 72 (+/- 19 SD) ng/ml in plasma and 925 (+/- 495 SD) ng/g in tumour tissue.,Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8690750/),[ng] / [g],92,95951,DB00445,Epirubicin
,8869103,AUC,"For each of the anthracyclines, the sum of the corrected AUC values (nmol/g/min) of the active compounds was calculated as 8812 for Dauno; 9320 for Epi-Dox; 10 986 for Dox and 15 163 for Leu-Dox.",Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8869103/),[nM] / [g·min],8812,102579,DB00445,Epirubicin
,8869103,AUC,"For each of the anthracyclines, the sum of the corrected AUC values (nmol/g/min) of the active compounds was calculated as 8812 for Dauno; 9320 for Epi-Dox; 10 986 for Dox and 15 163 for Leu-Dox.",Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8869103/),[nM] / [g·min],9320,102580,DB00445,Epirubicin
,8869103,AUC,"For each of the anthracyclines, the sum of the corrected AUC values (nmol/g/min) of the active compounds was calculated as 8812 for Dauno; 9320 for Epi-Dox; 10 986 for Dox and 15 163 for Leu-Dox.",Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8869103/),[nM] / [g·min],10 986,102581,DB00445,Epirubicin
,8869103,AUC,"For each of the anthracyclines, the sum of the corrected AUC values (nmol/g/min) of the active compounds was calculated as 8812 for Dauno; 9320 for Epi-Dox; 10 986 for Dox and 15 163 for Leu-Dox.",Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8869103/),[nM] / [g·min],15 163,102582,DB00445,Epirubicin
,9768822,alpha half-life,Pharmacologic studies of single agent dexrazoxane (originally studied as an antineoplastic agent) demonstrates an alpha half-life of approximately 30 minutes and a beta half-life of 2 to 4 hours.,Clinical pharmacology of dexrazoxane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9768822/),min,30,103351,DB00445,Epirubicin
,9768822,beta half-life,Pharmacologic studies of single agent dexrazoxane (originally studied as an antineoplastic agent) demonstrates an alpha half-life of approximately 30 minutes and a beta half-life of 2 to 4 hours.,Clinical pharmacology of dexrazoxane. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9768822/),h,2 to 4,103352,DB00445,Epirubicin
,21920350,growth inhibition rates,"The antitumor analysis using H22 and A549 mice xenograft models revealed that the growth inhibition rates of MDS-11P at 50 mg/kg (twice a day for three weeks) reached 59.4%, 60.5% respectively without obvious weight loss.",Effects of the novel vascular targeting agent MDS-11P on tumor vascularity and its antitumor activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21920350/),%,59.4,105348,DB00445,Epirubicin
,21920350,growth inhibition rates,"The antitumor analysis using H22 and A549 mice xenograft models revealed that the growth inhibition rates of MDS-11P at 50 mg/kg (twice a day for three weeks) reached 59.4%, 60.5% respectively without obvious weight loss.",Effects of the novel vascular targeting agent MDS-11P on tumor vascularity and its antitumor activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21920350/),%,60.5,105349,DB00445,Epirubicin
,31685080,EE%,"The EE% and DL% for EPI in EPI-FIDCR are 74.02±0.55 % and 3.78±0.28 %, respectively.",Preparation and pharmacokinetics of bifunctional epirubicin-loaded micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31685080/),%,74.02,109874,DB00445,Epirubicin
,31685080,DL%,"The EE% and DL% for EPI in EPI-FIDCR are 74.02±0.55 % and 3.78±0.28 %, respectively.",Preparation and pharmacokinetics of bifunctional epirubicin-loaded micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31685080/),%,3.78,109875,DB00445,Epirubicin
,31685080,IC50,"The IC50 values of EPI-FIDCR and EPI solution (EPI-Free) for tumor cells were 7.03 μg/mL and 5.54 μg/mL, showing that EPI-FIDCR still maintained strong cytotoxicity.",Preparation and pharmacokinetics of bifunctional epirubicin-loaded micelles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31685080/),[μg] / [ml],7.03,109876,DB00445,Epirubicin
,31685080,IC50,"The IC50 values of EPI-FIDCR and EPI solution (EPI-Free) for tumor cells were 7.03 μg/mL and 5.54 μg/mL, showing that EPI-FIDCR still maintained strong cytotoxicity.",Preparation and pharmacokinetics of bifunctional epirubicin-loaded micelles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31685080/),[μg] / [ml],5.54,109877,DB00445,Epirubicin
,10873078,MTD,"In conclusion, the MTD of this schedule is 10 mg/day and the DLTs are neutropenia and diarrhea.",Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10873078/),,10,110284,DB00445,Epirubicin
,1337040,relative bioavailability,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),,0.76,111813,DB00445,Epirubicin
,1337040,relative bioavailability,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),,0.45,111814,DB00445,Epirubicin
,1337040,relative bioavailability,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),,0.80,111815,DB00445,Epirubicin
,1337040,relative bioavailability,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),,0.73,111816,DB00445,Epirubicin
,1337040,relative bioavailability,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),%,100,111817,DB00445,Epirubicin
,1337040,F,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),,0.76,111818,DB00445,Epirubicin
,1337040,F,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),,0.45,111819,DB00445,Epirubicin
,1337040,F,"In three patients who were given intravenous and intrahepato-arterial injections (90 mg.m-2) of plain epirubicin and Lipiodol-drug complex, the relative bioavailability of Lipiodol-epirubicin complex (F = 0.76 and 0.45) was lower than that of plain epirubicin (F = 0.80 and 0.73) in two patients while it was approximately 100% (F = 1.06 and 1.20) in one patient.",Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1337040/),%,100,111820,DB00445,Epirubicin
,12196374,overall survival,"Of 29 patients with evaluable disease, there was one complete response and six partial responses [24% response rate [95% confidence interval (CI) 10% to 44%]], a median PFS of 22 weeks (95% CI 17-27 weeks) and median overall survival of 34 weeks (95% CI 19-49 weeks).",A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12196374/),weeks,34,117162,DB00445,Epirubicin
,12196374,t(max),"Capecitabine was rapidly absorbed after oral administration, with a t(max) of 1-2 h for capecitabine, DFCR (5'-deoxy-5-fluorocytidine) and DFUR (5'-deoxy-5-fluorouridine).",A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12196374/),h,1-2,117163,DB00445,Epirubicin
,24132922,MTD,The MTD of sorafenib was 400 mg daily.,Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24132922/),mg,400,118739,DB00445,Epirubicin
,31542274,area under the curve,"The area under the curve and maximum concentrations of epirubicin in plasma were 0.45 ± 0.18 μg min/mL and 0.13 ± 0.06 μg/mL, respectively, in the device group and 0.71 ± 0.45 μg min/mL and 0.22 ± 0.17 μg/mL, respectively, in the 3-way-stopcock group (P = .013 and P = .021, respectively).",Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542274/),[min·μg] / [ml],0.45,119271,DB00445,Epirubicin
,31542274,area under the curve,"The area under the curve and maximum concentrations of epirubicin in plasma were 0.45 ± 0.18 μg min/mL and 0.13 ± 0.06 μg/mL, respectively, in the device group and 0.71 ± 0.45 μg min/mL and 0.22 ± 0.17 μg/mL, respectively, in the 3-way-stopcock group (P = .013 and P = .021, respectively).",Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542274/),[min·μg] / [ml],0.71,119272,DB00445,Epirubicin
,31542274,maximum concentrations,"The area under the curve and maximum concentrations of epirubicin in plasma were 0.45 ± 0.18 μg min/mL and 0.13 ± 0.06 μg/mL, respectively, in the device group and 0.71 ± 0.45 μg min/mL and 0.22 ± 0.17 μg/mL, respectively, in the 3-way-stopcock group (P = .013 and P = .021, respectively).",Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542274/),[μg] / [ml],0.13,119273,DB00445,Epirubicin
,31542274,maximum concentrations,"The area under the curve and maximum concentrations of epirubicin in plasma were 0.45 ± 0.18 μg min/mL and 0.13 ± 0.06 μg/mL, respectively, in the device group and 0.71 ± 0.45 μg min/mL and 0.22 ± 0.17 μg/mL, respectively, in the 3-way-stopcock group (P = .013 and P = .021, respectively).",Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542274/),[μg] / [ml],0.22,119274,DB00445,Epirubicin
,31542274,tumor necrosis ratios,The tumor necrosis ratios at 48 hours were 62 ± 11% in the device group and 51 ± 13% in the 3-way-stopcock group (P = .039).,Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542274/),%,62,119275,DB00445,Epirubicin
,31542274,tumor necrosis ratios,The tumor necrosis ratios at 48 hours were 62 ± 11% in the device group and 51 ± 13% in the 3-way-stopcock group (P = .039).,Use of a Glass Membrane Pumping Emulsification Device Improves Systemic and Tumor Pharmacokinetics in Rabbit VX2 Liver Tumor in Transarterial Chemoembolization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542274/),%,51,119276,DB00445,Epirubicin
,1450047,half-lives,"Bolus injection was followed by a three exponential decay in plasma, with half-lives of 2.43 min, 1.95 h and 21.7 h; 48-h infusions were characterized by the very rapid establishment of a plasma plateau concentration followed by a biexponential decay after stopping the infusion.",Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1450047/),min,2.43,135219,DB00445,Epirubicin
,1450047,half-lives,"Bolus injection was followed by a three exponential decay in plasma, with half-lives of 2.43 min, 1.95 h and 21.7 h; 48-h infusions were characterized by the very rapid establishment of a plasma plateau concentration followed by a biexponential decay after stopping the infusion.",Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1450047/),h,1.95,135220,DB00445,Epirubicin
,1450047,half-lives,"Bolus injection was followed by a three exponential decay in plasma, with half-lives of 2.43 min, 1.95 h and 21.7 h; 48-h infusions were characterized by the very rapid establishment of a plasma plateau concentration followed by a biexponential decay after stopping the infusion.",Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1450047/),h,21.7,135221,DB00445,Epirubicin
,32381487,objective response rate,The objective response rate in the evaluable population was 11%.,"A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32381487/),%,11,135663,DB00445,Epirubicin
,3470504,detection limit,"The detection limit in plasma was 4 X 10(-8) M for the glucuronides, 7 X 10(-9) M for the glycosides, and 1 X 10(-9) M for the aglycones.","Analysis of doxorubicin, 4'-epidoxorubicin, and their metabolites by liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470504/),M,4 X 10(-8),136224,DB00445,Epirubicin
,3470504,detection limit,"The detection limit in plasma was 4 X 10(-8) M for the glucuronides, 7 X 10(-9) M for the glycosides, and 1 X 10(-9) M for the aglycones.","Analysis of doxorubicin, 4'-epidoxorubicin, and their metabolites by liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470504/),M,7 X 10(-9),136225,DB00445,Epirubicin
,3470504,detection limit,"The detection limit in plasma was 4 X 10(-8) M for the glucuronides, 7 X 10(-9) M for the glycosides, and 1 X 10(-9) M for the aglycones.","Analysis of doxorubicin, 4'-epidoxorubicin, and their metabolites by liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470504/),M,1 X 10(-9),136226,DB00445,Epirubicin
,3470504,detection limit,The detection limit in urine was approximately 5 X 10(-8) M. Plasma and urine of two patients who had received 4'-epidoxorubicin by iv bolus injection were analyzed.,"Analysis of doxorubicin, 4'-epidoxorubicin, and their metabolites by liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470504/),M,5 X,136227,DB00445,Epirubicin
,12123338,area under the concentration-time curve,"Paclitaxel administration significantly increased the epirubicinol area under the concentration-time curve, from 357+/-146 (epirubicin) to 603+/-107 (EP) and 640+/-81 h x ng/ml (GEP), and reduced the renal clearance of epirubicin and epirubicinol by 38 and 52.2% and 34.5 and 53% in GEP- and EP-treated patients, respectively, compared with epirubicin alone.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[h·ng] / [ml],357,143077,DB00445,Epirubicin
,12123338,area under the concentration-time curve,"Paclitaxel administration significantly increased the epirubicinol area under the concentration-time curve, from 357+/-146 (epirubicin) to 603+/-107 (EP) and 640+/-81 h x ng/ml (GEP), and reduced the renal clearance of epirubicin and epirubicinol by 38 and 52.2% and 34.5 and 53% in GEP- and EP-treated patients, respectively, compared with epirubicin alone.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[h·ng] / [ml],603,143078,DB00445,Epirubicin
,12123338,area under the concentration-time curve,"Paclitaxel administration significantly increased the epirubicinol area under the concentration-time curve, from 357+/-146 (epirubicin) to 603+/-107 (EP) and 640+/-81 h x ng/ml (GEP), and reduced the renal clearance of epirubicin and epirubicinol by 38 and 52.2% and 34.5 and 53% in GEP- and EP-treated patients, respectively, compared with epirubicin alone.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[h·ng] / [ml],640,143079,DB00445,Epirubicin
,12123338,tC0.1,"The only pharmacokinetic/pharmacodynamic relationship observed was between neutropenia and the time spent above the threshold plasma level of 0.1 micromol/l (tC0.1) of paclitaxel, with the time required to obtain a 50% decrease in neutrophil count (Et50) of GEP being 7.8 h, similar to that of EP.","Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123338/),[μM] / [l],0.1,143080,DB00445,Epirubicin
,27002506,maximal tolerated dose,The maximal tolerated dose was 100 mg given every 2 weeks.,Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27002506/),,100,149477,DB00445,Epirubicin
,27002506,response rate,"The response rate was 45 %; median progression-free survival was 10.4 months, whereas 54.6 months of median overall survival was achieved.",Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27002506/),%,45,149478,DB00445,Epirubicin
,27002506,progression-free survival,"The response rate was 45 %; median progression-free survival was 10.4 months, whereas 54.6 months of median overall survival was achieved.",Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27002506/),month,10.4,149479,DB00445,Epirubicin
,27002506,overall survival,"The response rate was 45 %; median progression-free survival was 10.4 months, whereas 54.6 months of median overall survival was achieved.",Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27002506/),month,54.,149480,DB00445,Epirubicin
,21290248,AUC,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[h·μg] / [ml],195.0,154011,DB00445,Epirubicin
,21290248,AUC,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[h·μg] / [ml],174.8,154012,DB00445,Epirubicin
,21290248,clearance,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[l] / [h],5.1,154013,DB00445,Epirubicin
,21290248,clearance,"The kinetic disposition of CYC was enantioselective in patients with breast cancer, with plasma accumulation of the (S)-(-)-CYC enantiomer (AUC 195.0 vs. 174.8 μg h/mL) due to the preferential clearance of the (R)-(+)CYC enantiomer (5.1 vs. 5.7 L/h).",Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21290248/),[l] / [h],5.7,154014,DB00445,Epirubicin
,10430255,progression free,Median progression free and overall survival were both 8 months.,Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430255/),month,8,155777,DB00445,Epirubicin
,10811677,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) of epirubicin was higher in the TE group (2,346 ng/mL. h v 1,717 ng/mL. h; P =.002).",Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10811677/),[ng] / [h·ml],"2,346",158274,DB00445,Epirubicin
,10811677,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) of epirubicin was higher in the TE group (2,346 ng/mL. h v 1,717 ng/mL. h; P =.002).",Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10811677/),[ng] / [h·ml],"1,717",158275,DB00445,Epirubicin
,10511918,area under the concentration-time curve (AUC),"Likewise, patients given epirubicin 90 mg/m2 had a sudden rebound of epirubicinol plasma concentrations shortly after the start of infusion of paclitaxel 200 mg/m2, with a significant increase in the area under the concentration-time curve (AUC) of epirubicinol as compared with epirubicin alone (1.27 +/- 0.2 vs 0.61 +/- 0.1 mumol/L.h).",Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511918/),[μM] / [h·l],1.27,161516,DB00445,Epirubicin
,10511918,area under the concentration-time curve (AUC),"Likewise, patients given epirubicin 90 mg/m2 had a sudden rebound of epirubicinol plasma concentrations shortly after the start of infusion of paclitaxel 200 mg/m2, with a significant increase in the area under the concentration-time curve (AUC) of epirubicinol as compared with epirubicin alone (1.27 +/- 0.2 vs 0.61 +/- 0.1 mumol/L.h).",Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511918/),[μM] / [h·l],0.61,161517,DB00445,Epirubicin
,25586675,z,"Optimized formulation had molar ratio of 60:30:8:2 (HSPC:Chol:DSPG:mPEG-DSPE) with entrapment efficiency ∼83%, particle size below 200 nm and zeta potential about -20 mV.",Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586675/),,20,163179,DB00445,Epirubicin
,25586675,IC50,"The IC50 value obtained for epirubicin solution, non-targeted and targeted liposomes was 0.675, 0.532 and 0.192 µg/ml, respectively.",Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586675/),[μg] / [ml],0.675,163180,DB00445,Epirubicin
,25586675,IC50,"The IC50 value obtained for epirubicin solution, non-targeted and targeted liposomes was 0.675, 0.532 and 0.192 µg/ml, respectively.",Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586675/),[μg] / [ml],0.532,163181,DB00445,Epirubicin
,25586675,IC50,"The IC50 value obtained for epirubicin solution, non-targeted and targeted liposomes was 0.675, 0.532 and 0.192 µg/ml, respectively.",Surface-modified Epirubicin-HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586675/),[μg] / [ml],0.192,163182,DB00445,Epirubicin
,20929434,tumor inhibitory rate,"The mean tumor inhibitory rate for EPI-LTSL, EPI-NTSL, and EPI-solution were 61.1, 39.6, and 43.1%, respectively.",Epirubicin-encapsulated long-circulating thermosensitive liposome improves pharmacokinetics and antitumor therapeutic efficacy in animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20929434/),%,61.1,164357,DB00445,Epirubicin
,20929434,tumor inhibitory rate,"The mean tumor inhibitory rate for EPI-LTSL, EPI-NTSL, and EPI-solution were 61.1, 39.6, and 43.1%, respectively.",Epirubicin-encapsulated long-circulating thermosensitive liposome improves pharmacokinetics and antitumor therapeutic efficacy in animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20929434/),%,39.6,164358,DB00445,Epirubicin
,20929434,tumor inhibitory rate,"The mean tumor inhibitory rate for EPI-LTSL, EPI-NTSL, and EPI-solution were 61.1, 39.6, and 43.1%, respectively.",Epirubicin-encapsulated long-circulating thermosensitive liposome improves pharmacokinetics and antitumor therapeutic efficacy in animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20929434/),%,43.1,164359,DB00445,Epirubicin
,18525298,MTD,The MTD of epirubicin was 50 mg/m2.,"Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18525298/),[mg] / [m2],50,165644,DB00445,Epirubicin
,6590528,Urine excretion,"Urine excretion amounts to a total of about 11% of the administered dose during 48 h after drug administration, and less than 1% during the following 48 h.",Pharmacokinetics of 4'-epi-doxorubicin in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6590528/),%,11,168039,DB00445,Epirubicin
less,6590528,Urine excretion,"Urine excretion amounts to a total of about 11% of the administered dose during 48 h after drug administration, and less than 1% during the following 48 h.",Pharmacokinetics of 4'-epi-doxorubicin in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6590528/),%,1,168040,DB00445,Epirubicin
,11761453,Peak plasma MEN-10755 levels,"Peak plasma MEN-10755 levels ranged between 474 and 21,587 microg/l.","Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11761453/),[μg] / [l],"474 and 21,587",168967,DB00445,Epirubicin
,11761453,elimination half-life (T(1/2gamma)),The mean elimination half-life (T(1/2gamma)) was 20.7+/-9.0 h.,"Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11761453/),h,20.7,168968,DB00445,Epirubicin
,11761453,plasma clearance,The mean plasma clearance of MEN-10755 was 6.0+/-2.2 l/h per m2 with a mean volume of distribution (Vss) of 95.6+/-43.4 l/m2.,"Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11761453/),[l] / [h·m2],6.0,168969,DB00445,Epirubicin
,11761453,volume of distribution (Vss),The mean plasma clearance of MEN-10755 was 6.0+/-2.2 l/h per m2 with a mean volume of distribution (Vss) of 95.6+/-43.4 l/m2.,"Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11761453/),[l] / [m2],95.6,168970,DB00445,Epirubicin
,11761453,renal excretion of unchanged drug,The mean renal excretion of unchanged drug within 24 h was 4.3+/-1.8%.,"Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11761453/),%,4.3,168971,DB00445,Epirubicin
,26410808,four,"Compared to 1st generation conjugate (P-EPI, Mw <50 kDa), 2P-EPI demonstrated remarkably improved PK such as fourfold terminal half-life (33.22 ± 3.18 h for 2P-EPI vs. 7.55 ± 3.18 h for P-EPI), which is primarily attributed to the increased molecular weight of the polymer carrier.",FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26410808/),h,33.22,173242,DB00445,Epirubicin
,26410808,terminal half-life,"Compared to 1st generation conjugate (P-EPI, Mw <50 kDa), 2P-EPI demonstrated remarkably improved PK such as fourfold terminal half-life (33.22 ± 3.18 h for 2P-EPI vs. 7.55 ± 3.18 h for P-EPI), which is primarily attributed to the increased molecular weight of the polymer carrier.",FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26410808/),h,33.22,173243,DB00445,Epirubicin
,26410808,terminal half-life,"Compared to 1st generation conjugate (P-EPI, Mw <50 kDa), 2P-EPI demonstrated remarkably improved PK such as fourfold terminal half-life (33.22 ± 3.18 h for 2P-EPI vs. 7.55 ± 3.18 h for P-EPI), which is primarily attributed to the increased molecular weight of the polymer carrier.",FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26410808/),h,7.55,173244,DB00445,Epirubicin
,2611038,half-life time of the alpha-phase,"Typically, the half-life time of the alpha-phase is 3-5 min and the terminal half-life time in the order 20-30 h.",Pharmacokinetics of anthracyclines. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611038/),min,3-5,175736,DB00445,Epirubicin
,2611038,terminal half-life time,"Typically, the half-life time of the alpha-phase is 3-5 min and the terminal half-life time in the order 20-30 h.",Pharmacokinetics of anthracyclines. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611038/),h,20-30,175737,DB00445,Epirubicin
,3470178,Plasma clearance,"Plasma clearance (nine patients, mean: 93.4 l/hr; range: 69.3-129.5 l/hr) is higher than the corresponding parameter determined in patients with hepatic metastases after intravenous therapy.",Intrahepatic arterial administration of 4'epidoxorubicin (epirubicin) in advanced cancer patients. A pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470178/),[l] / [h],93.4,177085,DB00445,Epirubicin
,3470178,plasma clearance,"The remaining patient is characterised by an abnormally low plasma clearance (13.6 l/hr), due to a hepato-pulmonary shunt.",Intrahepatic arterial administration of 4'epidoxorubicin (epirubicin) in advanced cancer patients. A pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3470178/),[l] / [h],13.6,177086,DB00445,Epirubicin
,2379173,peak concentration,Administration of the 150 mg/m2 dose over the 6 h compared to the bolus administration was associated with a 92% decrease in peak concentration from 3088 +/- 1503 to 234 +/- 126 ng/ml.,Pharmacokinetics and toxicity of two schedules of high dose epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379173/),[ng] / [ml],3088,179847,DB00445,Epirubicin
,2379173,peak concentration,Administration of the 150 mg/m2 dose over the 6 h compared to the bolus administration was associated with a 92% decrease in peak concentration from 3088 +/- 1503 to 234 +/- 126 ng/ml.,Pharmacokinetics and toxicity of two schedules of high dose epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379173/),[ng] / [ml],234,179848,DB00445,Epirubicin
,2379173,distribution half-life,The median distribution half-life was 10 min and the median elimination half-life was 42.0 h.,Pharmacokinetics and toxicity of two schedules of high dose epirubicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379173/),min,10,179849,DB00445,Epirubicin
,2379173,elimination half-life,The median distribution half-life was 10 min and the median elimination half-life was 42.0 h.,Pharmacokinetics and toxicity of two schedules of high dose epirubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379173/),h,42.0,179850,DB00445,Epirubicin
,3865777,total plasma clearance,The pharmacokinetic parameters of epirubicin were characterized by a high total plasma clearance (mean value: 70-85 1/hr) and a mean elimination half-life of 25-35 hr.,Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3865777/),[1] / [h],70-85,183310,DB00445,Epirubicin
,3865777,elimination half-life,The pharmacokinetic parameters of epirubicin were characterized by a high total plasma clearance (mean value: 70-85 1/hr) and a mean elimination half-life of 25-35 hr.,Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3865777/),h,25-35,183311,DB00445,Epirubicin
,3865777,cumulative urinary excretion,The cumulative urinary excretion was 11-12% of the dose administered and did not vary significantly as a function of time or dose.,Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3865777/),%,11-12,183312,DB00445,Epirubicin
,24101870,half-life,"The liposomes are characterized as stable, with very good pharmacokinetics (half-life 18.6 hours).",Vitamin C-driven epirubicin loading into liposomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24101870/),h,18.6,186056,DB00445,Epirubicin
,3460699,half-life,"In serum, a rapid initial distribution phase, with a half-life of about 5 minutes for DOX and 4 minutes for epi-DOX, was followed by a slower decrease in the drug levels.",Comparative pharmacokinetics of doxorubicin and epirubicin in patients with gastrointestinal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3460699/),min,5,186538,DB00445,Epirubicin
,3460699,half-life,"In serum, a rapid initial distribution phase, with a half-life of about 5 minutes for DOX and 4 minutes for epi-DOX, was followed by a slower decrease in the drug levels.",Comparative pharmacokinetics of doxorubicin and epirubicin in patients with gastrointestinal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3460699/),min,4,186539,DB00445,Epirubicin
,2040035,t1/2 gamma,"Large interindividual differences were demonstrated (mean t1/2 gamma, 21.6 +/- 7.9 h; range, 10.6-69 h; n = 110).",Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040035/),h,21.6,187706,DB00445,Epirubicin
,2040035,t1/2 gamma,"The metabolite epirubicinol appeared quickly after epirubicin administration and its half-lives were shorter than that of the parent compound (mean t1/2 gamma, 18.1 +/- 4.8 h; range, 8.2-38.4 h; n = 105).",Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040035/),h,18.1,187707,DB00445,Epirubicin
,2040035,t1/2 gamma,"Formation of the aglycone metabolite was delayed and the half-life of this metabolite was shorter than that of epirubicin (mean t1/2 gamma, 13 +/- 4.6 h; range, 2.7-29 h; n = 104).",Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2040035/),h,13,187708,DB00445,Epirubicin
,11804182,Response rates,Response rates in patients with visceral and liver metastases were 78% and 55% respectively.,Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11804182/),%,78,190849,DB00445,Epirubicin
,11804182,Response rates,Response rates in patients with visceral and liver metastases were 78% and 55% respectively.,Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11804182/),%,55,190850,DB00445,Epirubicin
,11804182,disease-free survival,"After a median follow-up of 19 months (12-36), median disease-free survival is 11 months and median overall survival has not been reached.",Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11804182/),month,11,190851,DB00445,Epirubicin
,12764671,clearance (CL),Individual clearance (CL) estimates ranged from 4 to 86 l/h and the final model included CL as a function of aspartate aminotransferase (AST): CL (l/h)=72.9-(72.9x0.135xlnAST).,A population model of epirubicin pharmacokinetics and application to dosage guidelines. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12764671/),[l] / [h],4 to 86,193805,DB00445,Epirubicin
,12764671,AUC,"Using a target AUC of 4000 ng.h/ml, the following doses were predicted to achieve this exposure with the greatest precision: AST <150 IU/l 125 mg; AST 150-250 IU/l 90 mg; AST 250-500 IU/l 60 mg; AST >500 IU/l 30 mg.",A population model of epirubicin pharmacokinetics and application to dosage guidelines. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12764671/),[h·ng] / [ml],4000,193806,DB00445,Epirubicin
,1341719,maximum plasma concentrations,"The median maximum plasma concentrations were 322, 316, 336 and 288 ng ml-1 in patients with CR, PR, SD and PD, respectively.",Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341719/),[ng] / [ml],322,195227,DB00445,Epirubicin
,1341719,maximum plasma concentrations,"The median maximum plasma concentrations were 322, 316, 336 and 288 ng ml-1 in patients with CR, PR, SD and PD, respectively.",Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341719/),[ng] / [ml],316,195228,DB00445,Epirubicin
,1341719,maximum plasma concentrations,"The median maximum plasma concentrations were 322, 316, 336 and 288 ng ml-1 in patients with CR, PR, SD and PD, respectively.",Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341719/),[ng] / [ml],336,195229,DB00445,Epirubicin
,1341719,maximum plasma concentrations,"The median maximum plasma concentrations were 322, 316, 336 and 288 ng ml-1 in patients with CR, PR, SD and PD, respectively.",Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1341719/),[ng] / [ml],288,195230,DB00445,Epirubicin
,11994057,AUC,"A significant increase in epirubicin AUC (+0.74 micromol l-1 h [95% CI for the difference: 0.14, 1.34] and +1.09 micromol l-1 h [95% CI for the difference: 0.44, 1.74]) and decrease in drug clearance (CLTB) (-25.35 l h-1 m-2[95% CI for the difference: -50.18, -0.52] and -35.9 l h-1 m-2[95% CI for the difference -63,4,-8,36]) occurred in combination with paclitaxel 200 and 225 mg m-2 with respect to the AUC (3.16+/-0.6 micromol l-1 h) and CLTB (74.4+/-28.4 l h-1 m-2) of epirubicin followed by paclitaxel 30 h later.",Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994057/),[h·μM] / [l],3.16,196498,DB00445,Epirubicin
,11994057,CLTB,"A significant increase in epirubicin AUC (+0.74 micromol l-1 h [95% CI for the difference: 0.14, 1.34] and +1.09 micromol l-1 h [95% CI for the difference: 0.44, 1.74]) and decrease in drug clearance (CLTB) (-25.35 l h-1 m-2[95% CI for the difference: -50.18, -0.52] and -35.9 l h-1 m-2[95% CI for the difference -63,4,-8,36]) occurred in combination with paclitaxel 200 and 225 mg m-2 with respect to the AUC (3.16+/-0.6 micromol l-1 h) and CLTB (74.4+/-28.4 l h-1 m-2) of epirubicin followed by paclitaxel 30 h later.",Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994057/),[l] / [(m)^2·h],74.4,196499,DB00445,Epirubicin
,11994057,tC0.1,The tC0.1 value predicted to yield a 50% decrease in neutrophil count was 7.7 h.,Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994057/),h,7.7,196500,DB00445,Epirubicin
,11249051,progression-free,"At five years progression-free and overall survival rates are 37.5% and 65%, respectively.",High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249051/),%,37.,199261,DB00445,Epirubicin
,11249051,overall survival,"At five years progression-free and overall survival rates are 37.5% and 65%, respectively.",High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249051/),%,65,199262,DB00445,Epirubicin
,9215819,peak plasma concentration,The mean peak plasma concentration of paclitaxel ranged between 5.1 and 6.2 micromol/L at doses of 175 to 225 mg/m2.,Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215819/),[μM] / [l],5.1 and 6.2,202728,DB00445,Epirubicin
,11304775,Response rate,Response rate was 76% (28% complete).,Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304775/),%,76,206733,DB00445,Epirubicin
,11304775,overall survival,Median overall survival was 29 months.,Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304775/),month,29,206734,DB00445,Epirubicin
,11304775,Urinary excretion,Urinary excretion of EPI dose went from 8.2% in E --> T to 11.8% in ET cycles.,Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304775/),%,8.2,206735,DB00445,Epirubicin
,11304775,Urinary excretion,Urinary excretion of EPI dose went from 8.2% in E --> T to 11.8% in ET cycles.,Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304775/),%,11.8,206736,DB00445,Epirubicin
,29373094,bpCR rates,"The bpCR rates were 51.7% and 42.0% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,51.7,209179,DB00445,Epirubicin
,29373094,bpCR rates,"The bpCR rates were 51.7% and 42.0% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,42.0,209180,DB00445,Epirubicin
,29373094,total pathologic complete response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,45.8,209181,DB00445,Epirubicin
,29373094,total pathologic complete response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,35.8,209182,DB00445,Epirubicin
,29373094,overall response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,96.3,209183,DB00445,Epirubicin
,29373094,overall response rates,"The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively.","Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29373094/),%,91.2,209184,DB00445,Epirubicin
,12915867,overall response rate,"Of 34 patients with evaluable disease, one patient had a complete response and nine patients had partial response, yielding an overall response rate of 29.4%.","Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915867/),%,29.4,212168,DB00445,Epirubicin
,22607766,MTD,"The MTD of ixabepilone in combination with epirubicin 75 mg/m(2) was 30 mg/m(2), and the DLT dose was 35 mg/m(2) with grade 4 neutropenia.",A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22607766/),,30,212954,DB00445,Epirubicin
,2225316,terminal half-life,The terminal half-life from 24 to 72 h was not significantly changed by the partial hepatectomy.,The influence of partial hepatectomy on the pharmacokinetics of preoperatively injected 4'-epidoxorubicin in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225316/),h,24 to 72,214763,DB00445,Epirubicin
,2225316,fraction of unbound Epi-A,The fraction of unbound Epi-A was 0.16 in partially hepatectomized animals and 0.20 in sham-operated rats.,The influence of partial hepatectomy on the pharmacokinetics of preoperatively injected 4'-epidoxorubicin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225316/),,0.16,214764,DB00445,Epirubicin
,2225316,fraction of unbound Epi-A,The fraction of unbound Epi-A was 0.16 in partially hepatectomized animals and 0.20 in sham-operated rats.,The influence of partial hepatectomy on the pharmacokinetics of preoperatively injected 4'-epidoxorubicin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225316/),,0.20,214765,DB00445,Epirubicin
,6342772,plasma clearance,"A high plasma clearance (0.9-1.41/min), a terminal half-life of about 30-40 hr and a large volume of distribution were the main pharmacokinetic characteristics of 4'-epi-DX.","4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6342772/),1/[min],0.9-1.41,219247,DB00445,Epirubicin
,6342772,terminal half-life,"A high plasma clearance (0.9-1.41/min), a terminal half-life of about 30-40 hr and a large volume of distribution were the main pharmacokinetic characteristics of 4'-epi-DX.","4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6342772/),h,30-40,219248,DB00445,Epirubicin
,8304970,ID50 concentration,Since the ID50 concentration for Ro11-2933 is 17.7 microM (5-12-fold less than the other modifiers) we have used isobologram analysis to demonstrate that the interaction with doxorubicin is supra-additive and cannot be explained by additive toxicity.,"Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8304970/),μM,17.7,228549,DB00445,Epirubicin
,2363946,maximum plasma concentrations,Measured maximum plasma concentrations of epirubicin during 2 hours' constant rate infusions of 70 mg m-2 to patients with lymphoma (median age: 46.5 years) were within the range 171-404 ng ml-1 (median value: 265 ng ml-1).,Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363946/),[ng] / [ml],171-404,234537,DB00445,Epirubicin
,2363946,maximum plasma concentrations,Measured maximum plasma concentrations of epirubicin during 2 hours' constant rate infusions of 70 mg m-2 to patients with lymphoma (median age: 46.5 years) were within the range 171-404 ng ml-1 (median value: 265 ng ml-1).,Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363946/),[ng] / [ml],265,234538,DB00445,Epirubicin
,11087080,retention times,"Using this system, the retention times for docetaxel and paclitaxel are 8.5 min and 10.5 min, respectively, with good resolution and without any interference from endogenous plasma constituents or docetaxel metabolites at these retention times.",Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11087080/),min,8.5,238176,DB00445,Epirubicin
,11087080,retention times,"Using this system, the retention times for docetaxel and paclitaxel are 8.5 min and 10.5 min, respectively, with good resolution and without any interference from endogenous plasma constituents or docetaxel metabolites at these retention times.",Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11087080/),min,10.5,238177,DB00445,Epirubicin
,11087080,total run time needed,The total run time needed is only 13 min.,Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11087080/),min,13,238178,DB00445,Epirubicin
,7695982,Clearance,"Clearance, volume of distribution and half-life of the drug were 3.48 +/- 0.88 1/h/m2, 0.56 +/- 0.22 l/kg and 4.68 +/- 2.01 h, respectively.","Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695982/),[1] / [h·m2],3.48,239318,DB00445,Epirubicin
,7695982,volume of distribution,"Clearance, volume of distribution and half-life of the drug were 3.48 +/- 0.88 1/h/m2, 0.56 +/- 0.22 l/kg and 4.68 +/- 2.01 h, respectively.","Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695982/),[l] / [kg],0.56,239319,DB00445,Epirubicin
,7695982,half-life,"Clearance, volume of distribution and half-life of the drug were 3.48 +/- 0.88 1/h/m2, 0.56 +/- 0.22 l/kg and 4.68 +/- 2.01 h, respectively.","Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695982/),h,4.68,239320,DB00445,Epirubicin
,7695982,total recovery,"Variation in recovery of the metabolites in urine varied over an even wider range, total recovery varying from 17.5 to 81.8% of the dose administered.","Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7695982/),%,17.5 to 81.8,239321,DB00445,Epirubicin
,22884505,C(trough),The geometric mean presurgery C(trough) was 51·8 μg/mL (coefficient of variation 52·5%) in the intravenous group and 69·0 μg/mL (55·8%) in the subcutaneous group.,"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884505/),[μg] / [ml],51·8,240404,DB00445,Epirubicin
,22884505,C(trough),The geometric mean presurgery C(trough) was 51·8 μg/mL (coefficient of variation 52·5%) in the intravenous group and 69·0 μg/mL (55·8%) in the subcutaneous group.,"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22884505/),[μg] / [ml],69·0,240405,DB00445,Epirubicin
,8230753,maximum tolerated dose,Granulocytopenia was found to be the dose limiting toxicity with a maximum tolerated dose of 150 mg/m2/course.,Pharmacokinetic re-evaluation and phase I study of high dose epirubicin in advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230753/),[mg] / [course·m2],150,243706,DB00445,Epirubicin
,25085588,C max,"C max in there groups after administration was 28.77 ± 7.15 μg/ml in c-TACE group, 83.84 ± 32.28 μg/ml in GSMs-TACE group, and 238.46 ± 23.44 μg/ml in HAI group at 5 min, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),[μg] / [ml],28.77,249199,DB00445,Epirubicin
,25085588,C max,"C max in there groups after administration was 28.77 ± 7.15 μg/ml in c-TACE group, 83.84 ± 32.28 μg/ml in GSMs-TACE group, and 238.46 ± 23.44 μg/ml in HAI group at 5 min, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),[μg] / [ml],83.84,249200,DB00445,Epirubicin
,25085588,C max,"C max in there groups after administration was 28.77 ± 7.15 μg/ml in c-TACE group, 83.84 ± 32.28 μg/ml in GSMs-TACE group, and 238.46 ± 23.44 μg/ml in HAI group at 5 min, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),[μg] / [ml],238.46,249201,DB00445,Epirubicin
,25085588,concentration,"The epirubicin concentration in tumor tissue was 53.06 ± 16.9 μg/g in c-TACE group, 44.49 ± 16.80 μg/g in the GSMs-TACE group, and 18.32 ± 8.30 μg/g in HAI group, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),μ,44,249202,DB00445,Epirubicin
,25085588,concentration,"The epirubicin concentration in tumor tissue was 53.06 ± 16.9 μg/g in c-TACE group, 44.49 ± 16.80 μg/g in the GSMs-TACE group, and 18.32 ± 8.30 μg/g in HAI group, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),,18,249203,DB00445,Epirubicin
,25085588,area under the curve (AUC) at 0-120 min,"The area under the curve (AUC) at 0-120 min in c-TACE, GSMs-TACE, and HAI groups were 1,815 ± 889.88, 3,416 ± 799.90, and 11,899 ± 2,717.17 μg min/ml, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),[min·μg] / [ml],"1,815",249204,DB00445,Epirubicin
,25085588,area under the curve (AUC) at 0-120 min,"The area under the curve (AUC) at 0-120 min in c-TACE, GSMs-TACE, and HAI groups were 1,815 ± 889.88, 3,416 ± 799.90, and 11,899 ± 2,717.17 μg min/ml, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),[min·μg] / [ml],"3,416",249205,DB00445,Epirubicin
,25085588,area under the curve (AUC) at 0-120 min,"The area under the curve (AUC) at 0-120 min in c-TACE, GSMs-TACE, and HAI groups were 1,815 ± 889.88, 3,416 ± 799.90, and 11,899 ± 2,717.17 μg min/ml, respectively.",Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25085588/),[min·μg] / [ml],"11,899",249206,DB00445,Epirubicin
,25769281,zeta potential,"Developed formulation revealed particle size, 235.3±15.12 nm, zeta potential, -27.5±0.7 mV and drug content (39.12±2.13 μg/mg), with spherical shape and smooth surface.","Biodegradable polymeric nanoparticles for oral delivery of epirubicin: In vitro, ex vivo, and in vivo investigations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25769281/),mv,-,250608,DB00445,Epirubicin
,25769281,zeta potential,"Developed formulation revealed particle size, 235.3±15.12 nm, zeta potential, -27.5±0.7 mV and drug content (39.12±2.13 μg/mg), with spherical shape and smooth surface.","Biodegradable polymeric nanoparticles for oral delivery of epirubicin: In vitro, ex vivo, and in vivo investigations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25769281/),mv,27.5,250609,DB00445,Epirubicin
,1551178,clearance,"For example, a 25-year-old man would display an average clearance of 95 l/h, whereas a 70-year-old woman would exhibit an average clearance of 64 l/h.",Variability in the pharmacokinetics of epirubicin: a population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1551178/),[l] / [h],95,250957,DB00445,Epirubicin
,1551178,clearance,"For example, a 25-year-old man would display an average clearance of 95 l/h, whereas a 70-year-old woman would exhibit an average clearance of 64 l/h.",Variability in the pharmacokinetics of epirubicin: a population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1551178/),[l] / [h],64,250958,DB00445,Epirubicin
,31830661,limit of,Validation data confirmed that the limit of detection and limit of quantification was 0.25 ng/mL and 0.5 ng/mL in both matrices.,"Development and validation of a high-performance liquid chromatographic method with a fluorescence detector for the analysis of epirubicin in human urine and plasma, and its application in drug monitoring. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31830661/),[ng] / [ml],0.25,251785,DB00445,Epirubicin
,31830661,limit of quantification,Validation data confirmed that the limit of detection and limit of quantification was 0.25 ng/mL and 0.5 ng/mL in both matrices.,"Development and validation of a high-performance liquid chromatographic method with a fluorescence detector for the analysis of epirubicin in human urine and plasma, and its application in drug monitoring. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31830661/),[ng] / [ml],0.5,251786,DB00445,Epirubicin
,16357174,t(1/2),Pharmacokinetic and biodistribution studies confirmed long circulation times (t(1/2) = 21 hours) and efficient accumulation in tumors (up to 15% ID/g) irrespective of the presence of the targeting ligand.,Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16357174/),h,21,253278,DB00445,Epirubicin
,28222073,area under the curve,Maximum tolerated dose for the combination was 240 mg per day oral rucaparib and carboplatin area under the curve 5 mg ml-1 min-1.,A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28222073/),[mg] / [min·ml],5,255887,DB00445,Epirubicin
≈,28222073,half-life,"Oral rucaparib demonstrated dose-proportional kinetics, a long half-life (≈17 h), and good bioavailability (36%).",A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28222073/),h,17,255888,DB00445,Epirubicin
,28222073,bioavailability,"Oral rucaparib demonstrated dose-proportional kinetics, a long half-life (≈17 h), and good bioavailability (36%).",A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28222073/),%,36,255889,DB00445,Epirubicin
,21040218,maximal tolerated doses,"The maximal tolerated doses in mice of NC-6300 and native epirubicin were 25 and 9 mg/kg, respectively, when administered three times with a 4-day interval between each dose.","Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040218/),[mg] / [kg],25,261786,DB00445,Epirubicin
,21040218,maximal tolerated doses,"The maximal tolerated doses in mice of NC-6300 and native epirubicin were 25 and 9 mg/kg, respectively, when administered three times with a 4-day interval between each dose.","Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040218/),[mg] / [kg],9,261787,DB00445,Epirubicin
,17009648,area under the concentration/time curve (AUC),The carboplatin dose was chosen to produce a target area under the concentration/time curve (AUC) of 5.0 microg-min/ml according to a published formula.,Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis--case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17009648/),[μg-min] / [ml],5.0,262418,DB00445,Epirubicin
,17009648,AUCs,"Pharmacokinetic studies showed that the AUCs of free platinum were 8.03 and 5.69 microg-min/ml in the first and second courses of the chemotherapy, respectively, suggesting that the AUC of carboplatin is affected by hemodialysis.",Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis--case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17009648/),[μg-min] / [ml],8.03,262419,DB00445,Epirubicin
,17009648,AUCs,"Pharmacokinetic studies showed that the AUCs of free platinum were 8.03 and 5.69 microg-min/ml in the first and second courses of the chemotherapy, respectively, suggesting that the AUC of carboplatin is affected by hemodialysis.",Pharmacokinetic analysis of paclitaxel and carboplatin in a patient with advanced ovarian cancer during hemodialysis--case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17009648/),[μg-min] / [ml],5.69,262420,DB00445,Epirubicin
,3458430,t1/2 alpha,"The mean t1/2 alpha, beta, and gamma were 4.67 min, 1.15 h, and 36.5 h, respectively, which were characterized by a short distribution phase (alpha) and a prolonged elimination phase (gamma).",[Pharmacokinetics of epirubicin in cancer patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458430/),min,4.67,264601,DB00445,Epirubicin
,3458430,beta,"The mean t1/2 alpha, beta, and gamma were 4.67 min, 1.15 h, and 36.5 h, respectively, which were characterized by a short distribution phase (alpha) and a prolonged elimination phase (gamma).",[Pharmacokinetics of epirubicin in cancer patients]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458430/),h,1.15,264602,DB00445,Epirubicin
,3458430,beta,"The mean t1/2 alpha, beta, and gamma were 4.67 min, 1.15 h, and 36.5 h, respectively, which were characterized by a short distribution phase (alpha) and a prolonged elimination phase (gamma).",[Pharmacokinetics of epirubicin in cancer patients]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458430/),h,36.5,264603,DB00445,Epirubicin
,3458430,gamma,"The mean t1/2 alpha, beta, and gamma were 4.67 min, 1.15 h, and 36.5 h, respectively, which were characterized by a short distribution phase (alpha) and a prolonged elimination phase (gamma).",[Pharmacokinetics of epirubicin in cancer patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458430/),h,36.5,264604,DB00445,Epirubicin
,3458430,V1,"The distribution volume of the central compartment (V1 = 0.351 l/kg) was small, while that of the tissue compartment (V2 = 0.254, V3 = 45.8 l/kg) was large, which could be explained by the binding of the drug to cellular components.",[Pharmacokinetics of epirubicin in cancer patients]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458430/),[l] / [kg],0.351,264605,DB00445,Epirubicin
,3458430,V2,"The distribution volume of the central compartment (V1 = 0.351 l/kg) was small, while that of the tissue compartment (V2 = 0.254, V3 = 45.8 l/kg) was large, which could be explained by the binding of the drug to cellular components.",[Pharmacokinetics of epirubicin in cancer patients]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458430/),,0.254,264606,DB00445,Epirubicin
,3458430,V3,"The distribution volume of the central compartment (V1 = 0.351 l/kg) was small, while that of the tissue compartment (V2 = 0.254, V3 = 45.8 l/kg) was large, which could be explained by the binding of the drug to cellular components.",[Pharmacokinetics of epirubicin in cancer patients]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3458430/),[l] / [kg],45.8,264607,DB00445,Epirubicin
,24621591,AUC,"The liposomal EPI formulation is eliminated slowly with an AUC of 7.6487, while the free drug has an AUC of only 0.0097.",Efficient human breast cancer xenograft regression after a single treatment with a novel liposomal formulation of epirubicin prepared using the EDTA ion gradient method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24621591/),,7.6487,266106,DB00445,Epirubicin
,24621591,AUC,"The liposomal EPI formulation is eliminated slowly with an AUC of 7.6487, while the free drug has an AUC of only 0.0097.",Efficient human breast cancer xenograft regression after a single treatment with a novel liposomal formulation of epirubicin prepared using the EDTA ion gradient method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24621591/),,0.0097,266107,DB00445,Epirubicin
,23203544,peak concentration,"The peak concentration of epirubicin in the MP group and the ID group were 21.84±18.85 ng/mL and 294.80±225.54 ng/mL, respectively.",Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23203544/),[ng] / [ml],21.84,268477,DB00445,Epirubicin
,23203544,peak concentration,"The peak concentration of epirubicin in the MP group and the ID group were 21.84±18.85 ng/mL and 294.80±225.54 ng/mL, respectively.",Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23203544/),[ng] / [ml],294.80,268478,DB00445,Epirubicin
,8622075,maximal rate of elimination (Vmax),"The data for 5-FU were best described by a one-compartment model with nonlinear elimination, where the maximal rate of elimination (Vmax) and the concentration at which the elimination was half-maximal (Km) were 105 mg/L.h and 27 mg/L, respectively.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),[mg] / [h·l],105,269720,DB00445,Epirubicin
,8622075,concentration at which the elimination was half-maximal (Km),"The data for 5-FU were best described by a one-compartment model with nonlinear elimination, where the maximal rate of elimination (Vmax) and the concentration at which the elimination was half-maximal (Km) were 105 mg/L.h and 27 mg/L, respectively.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),[mg] / [l],27,269721,DB00445,Epirubicin
,8622075,terminal half-life,"EPI concentration-time profiles showed a triexponential decline, with a mean terminal half-life of 24 hours and a clearance (CL) of 59 L/h.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),h,24,269722,DB00445,Epirubicin
,8622075,clearance (CL),"EPI concentration-time profiles showed a triexponential decline, with a mean terminal half-life of 24 hours and a clearance (CL) of 59 L/h.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),[l] / [h],59,269723,DB00445,Epirubicin
,8622075,half-life,"The elimination of 4-OHCP was monoexponential, with a mean half-life of 7 hours.","Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622075/),h,7,269724,DB00445,Epirubicin
,1995359,initial plasma clearance,"Thus the initial plasma clearance after six perfusions was 39 +/- 9, and 36 +/- 11 ml/min/kg in the epirubicin and saline groups respectively.",Effect of repeated intraperitoneal chemotherapy with epirubicin on the hepatic transport of bile acids and their enterohepatic circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1995359/),[ml] / [kg·min],39,273508,DB00445,Epirubicin
,1995359,initial plasma clearance,"Thus the initial plasma clearance after six perfusions was 39 +/- 9, and 36 +/- 11 ml/min/kg in the epirubicin and saline groups respectively.",Effect of repeated intraperitoneal chemotherapy with epirubicin on the hepatic transport of bile acids and their enterohepatic circulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1995359/),[ml] / [kg·min],36,273509,DB00445,Epirubicin
,1995359,excretory efficiency,The excretory efficiency of the liver at this stage was identical: 67 +/- 10% in the epirubicin treated animals and 67 +/- 6% in the saline controls.,Effect of repeated intraperitoneal chemotherapy with epirubicin on the hepatic transport of bile acids and their enterohepatic circulation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1995359/),%,67,273510,DB00445,Epirubicin
,1995359,excretory efficiency,The excretory efficiency of the liver at this stage was identical: 67 +/- 10% in the epirubicin treated animals and 67 +/- 6% in the saline controls.,Effect of repeated intraperitoneal chemotherapy with epirubicin on the hepatic transport of bile acids and their enterohepatic circulation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1995359/),%,67,273511,DB00445,Epirubicin
